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BACKGROUND: Sexual dysfunction (SD) is prevalent in patients with major depressive disorder 
(MDD) and is also associated with second-generation antidepressants (SGAD) which are 
commonly used to treat the condition. Evidence indicates underreporting of SD in efficacy 
studies. SD associated with antidepressant treatment is a serious side effect that may lead to 
early termination of treatment and worsening of quality of life. OBJECTIVES:  To systematically 
assess the harms of SD associated with SGAD in adult patients with MDD by drug type. 
METHODS: We retrieved English-language abstracts from PubMed, EMBASE, the Cochrane 
Library, PsycINFO, and International Pharmaceutical Abstracts from 1980 to October 2012 as 
well as from reference lists of pertinent review articles and grey literature searches. Two 
independent reviewers identified randomized controlled trials (RCTs) of at least six weeks' 
duration and observational studies with at least 1,000 participants. STUDY SELECTION: 
Reviewers abstracted data on study design, conduct, participants, interventions, outcomes and 
method of SD ascertainment, and rated risk of bias. A senior reviewer checked and confirmed 
extracted data and risk of bias ratings. ANALYSES: Random effects network meta-analysis using 
Bayesian methods for data from head-to-head trials and placebo-controlled comparisons; 
descriptive analyses calculating weighted mean rates from individual trials and observational 
studies. RESULTS/ SYNTHESIS: Data from sixty-three studies of low and moderate risk of bias 
(58 RCTs, five observational studies) with more than 26,000 patients treated with SGAD were 
included. Based on network meta-analyses of 66 pairwise comparisons from 37 RCTs, most 
comparisons showed a similar risk of sexual dysfunction among included SGAD. Credible 
intervals, however, were wide and included differences that would be considered clinically 
relevant. We observed three main patterns: Bupropion had a statistically significantly lower risk 
of sexual dysfunction than some other SGAD, and both escitalopram, and paroxetine showed a 
statistically significantly higher risk of sexual dysfunction than some other SGAD. We found 
reporting of harms related to sexual dysfunction inconsistent and insufficient in some trials. 
LIMITATIONS: Most trials were conducted in highly selected populations. Search was restricted 
to English-language only. CONCLUSION AND IMPLICATIONS: Because of the indirect nature of 
the comparisons, the often wide credible intervals, and the high variation in magnitude of 
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outcome, we rated the overall strength of evidence with respect to our findings low. The current 
degree of evidence does not allow a precise estimate of comparative risk of sexual dysfunction 
associated with a specific antidepressant. In the absence of such evidence, clinicians need to be 
aware of SD as a common adverse event and should discuss patients' preferences before 
initiating antidepressant therapy. 
 
1. Introduction 
Major depressive disorder (MDD) is one of the leading causes of disability worldwide, 
affecting 15 percent of the population in high-income countries once in their lifetime [1]. 
Antidepressants were the most frequently dispensed prescription drugs in the United 
States (US) in 2011 accounting for $11 billion in sales and 264 million prescriptions 
filled [2]. Sexual dysfunction, which can involve any or all phases of the sexual response 
cycle (i.e., libido, arousal, orgasm and ejaculation), is associated with both the condition 
and the treatments used, can affect up to 50 percent of untreated depressed patients [3, 
4]. Particularly when treated with second-generation antidepressants (SGAD), 
depressed patients may experience antidepressant-induced sexual dysfunction [5].  
 
Treatment-emergent sexual dysfunction is a frequent but often under-reported serious 
adverse event associated with the use of SGAD. According to the U.S. Food and Drug 
Administration (FDA), all adverse events resulting in a substantial disruption of a 
person's ability to conduct normal life functions can be considered serious adverse 
events [6]. Onset or worsening of sexual dysfunction as an adverse event associated 
with antidepressant use can result in premature discontinuation of antidepressant 
treatment, relapse of depression, and worsened health outcomes and quality of life [7-
9]. 
 
Rates of treatment-emergent sexual dysfunction in depressed patients from randomized 
clinical trials range from 15 to 80 percent [10, 11]. Using data from a cross-sectional 
study in Europe, study authors estimated the prevalence of treatment-emergent sexual 
dysfunction in depressed patients prescribed either a selective serotonin reuptake 
inhibitor or serotonin-noradrenaline reuptake inhibitors to be between 37.1 percent 
and 61.5 percent [12]. Evidence indicates underreporting of sexual dysfunction in 
efficacy studies, particularly when no targeted or structured method is used to obtain 
information on sexual functioning, both at baseline and throughout drug treatment [13]. 
In a prospective observational study, investigators observed a considerably lower 
incidence of antidepressant-associated sexual dysfunction when sexual dysfunction was 
determined by spontaneous reports of study participants alone compared to using a 
validated sexual function-specific instrument: nearly 80 percent of those with 
treatment-emergent sexual dysfunction would have gone undiagnosed if only reported 
spontaneously [14].  
 
A few systematic reviews addressed the issue of sexual dysfunction associated with 
SGAD in patients with MDD [10, 15-19]. With the exception of an updated meta-analysis 
by Gartlehner et al. [11], which also included data from observational studies, previous 
systematic reviews focused on efficacy trials. This study aims to systematically review 
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and assess the comparative harms of sexual dysfunction in MDD patients treated with 
SGAD using data from both clinical trials and observational studies.  
2. Methods 
This systematic review updates part of a larger comparative effectiveness review on 
SGAD funded by and conducted for the U.S. Agency for Healthcare Research and Quality 
(AHRQ) [19].  
 
2.1. Data Sources and Study Selection 
We searched PubMed, EMBASE, PsycINFO, the Cochrane Library, and International 
Pharmaceutical Abstracts from 1980 to October, 2012. We used Medical Subject 
Headings as search terms when available or key words when appropriate. We combined 
terms for MDD with a list of 13 specific SGAD (bupropion, citalopram, desvenlafaxine, 
duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, nefazodone, paroxetine, 
sertraline, trazodone, and venlafaxine) and their specific trade names. We limited the 
electronic search to "adult 19+ years," "human," and "English language." We used semi-
automated manual searches of reference lists of pertinent review articles and letters to 
the editor employing the ScopusTM citation database (www.scopus.com) [20]. The 
Scientific Resource Center (SRC) searched the following sources for potentially relevant 
unpublished literature: the U.S. FDA website, Health Canada, Authorized Medicines for 
the European Union, ClinicalTrials.gov, Current Controlled Trials, Clinical Study Results, 
World Health Organization Clinical Trials, Conference Papers Index, National Institutes 
of Health RePORTER, HSRProj, Hayes, Inc. Health Technology Assessment, and the New 
York Academy of Medicine’s Grey Literature Index. The SRC also asked pharmaceutical 
manufacturers to submit dossiers on completed research for each drug included in this 
review. We received dossiers from two firms (Astra Zeneca, London, United Kingdom 
[UK] and Warner Chilcott, Dublin, Ireland). 
 
Two investigators independently reviewed abstracts and full text articles (each done by 
two out of the authors: UR, GG, LCM, AG, BN, RAH, MVN, LL, BNG). We excluded studies 
available in abstract form only. We developed eligibility criteria with respect to study 
design, duration, patient population, interventions, and outcomes to assess sexual 
dysfunction as harms associated with SGAD or as treatment-emergent sexual 
dysfunction in adult inpatients and outpatients with MDD. We included head-to-head 
RCTs of at least six weeks’ duration comparing SGAD. Since head-to-head evidence was 
lacking for many comparisons, we also included placebo-controlled trials. We also 
examined data from observational studies with ≥1000 study participants and follow-up 
of at least 12 weeks. To be eligible for inclusion, a study had to report any health 
outcome related to sexual dysfunction, either as an adverse event (spontaneously 
reported by patients, systematically elicited, openly inquired, or observed by study 
clinicians), or as patient-rated or expert-rated outcomes of sexual dysfunction 
prospectively measured by a specific, validated instrument. We excluded studies that 
both reviewers agreed did not meet eligibility criteria. Discrepancies were resolved by 
discussion between both reviewers or, when necessary, by involving a third reviewer 
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(see Electronic Supplementary Material 1 for information on characteristics of included 
studies, and Electronic Supplementary Material 2 for information on the Update search 
strategy).  
2.2. Quality Assessment and Data Extraction  
Two trained reviewers (two at a time out of UR, AG, BN, MVN) independently abstracted 
data from each study and assigned an initial risk of bias (quality) assessment using 
predefined criteria based on those developed by the Cochrane Collaboration (low, 
moderate, and high risk of bias) [21]. To assess the risk of bias in observational studies, 
we used criteria outlined by Deeks and colleagues [22]. Any disagreement was resolved 
by consensus between the respective two reviewers. A senior reviewer (one at a time 
out of GG, LCM, RAH, LL, BNG) evaluated completeness of data abstraction and 
confirmed the quality assessment. If disagreements occurred, they were resolved by 
consensus. We abstracted information on study characteristics (study design, eligibility 
criteria), intervention (drugs, dose, duration), study participants, sample size, loss to 
follow-up, withdrawals because of adverse events, method of determining and reporting 
harms-related data and outcomes associated with sexual dysfunction. We used the 
Evidence-based Practice Center approach, conceptually similar to the GRADE (Grading 
of Recommendations Assessment, Development and Evaluation) system, to assign an 
overall grade for strength of evidence (low, moderate, or high strength of evidence) of 
the outcome [23].  
2.3. Data Synthesis and Analyses 
To be included in the quantitative analysis, studies had to provide sufficient data to 
calculate measures of incidence of sexual dysfunction. We recalculated rates of sexual 
dysfunction for each study using the number of all randomized patients as the 
denominator to reflect a true intention-to-treat (ITT) analysis. For statistical reasons we 
combined all reported subtypes of sexual dysfunction (e.g. anorgasmia, ejaculation 
failure, ejaculation disorder, erectile dysfunction, delayed ejaculation, abnormal orgasm, 
decreased libido and loss of libido) into one outcome category of sexual dysfunction. 
When available, sex-specific rates were abstracted. 
 
We conducted a network meta-analysis using Bayesian methods to compare rates of 
sexual dysfunction between SGAD, including both head-to-head trials comparing active 
interventions and placebo-controlled comparisons. To be included in the network meta-
analysis, RCTs had to fulfill (1) the general study eligibility criteria, and (2) the statistical 
conditions required for network meta-analysis (consistency, heterogeneity, geometry of 
treatment network). We used the methods developed and illustrated in NICE Technical 
Support Document 2, which details the generalized linear modeling framework for 
network meta-analyses of RCTs [24]. We used a random effects logistic regression 
model adjusting for correlations between multiple-arms within each study. Study effect 
and outcome effect parameters were modeled by noninformative (flat) prior 
distributions that were normal (0, 10000). For the heterogeneity of the random-effects 
model, we used a uniform prior distribution centered at zero with sufficiently large 
variance. The first 20,000 simulations were discarded to allow for model convergence 
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and then a further 100,000 simulations were used in estimating the posterior 
probabilities. Convergence was verified by trace plots and inspection of the Gelman-
Rubin statistic for monitored parameters. Our outcome measure was adverse events of 
sexual dysfunction. To assess the consistency between the different reporting methods, 
we conducted a sensitivity analysis, including studies where sexual dysfunction was 
determined only by open question or spontaneous patient reports. The network meta-
analysis was performed using WinBUGS Version 1.4.3, a Bayesian software package that 
uses Markov chain Monte Carlo (MCMC) methods. We calculated odds ratios and 95% 
credible intervals (CrI) for all possible pairwise comparisons among our drugs of 
interest. We analyzed RCTs reporting only male-specific rates separately from RCTs 
reporting total rates of sexual dysfunction. Only a small number of trials included in the 
network meta-analysis reported sex-specific rates. We used all data from these trials 
combining male and female rates into total rates along with data from trials reporting 
total rates of sexual dysfunction only. 
 
We conducted descriptive analyses, when conditions to perform comparative analyses 
could not be met. For studies providing only sex-specific rates of sexual dysfunction, we 
calculated weighted mean rates and 95% confidence intervals on sex-specific rates of 
sexual dysfunction pooling data from arms of both the active drug comparator and 
placebo-controlled trials. We calculated all descriptive analyses using StatsDirect 
Statistical Software, version 2.7.9 (StatsDirect, Cheshire, United Kingdom). Due to 
differences in study design, we could not pool rates from all observational studies and 
also present rates from individual studies. For both, the descriptive analyses and the 
network meta-analysis, we also included RCTs that did not report any baseline 
assessment of sexual dysfunction. 
3. Results 
Our searches identified 4,476 citations (see PRISMA flow-diagram, Fig. 1) [25] for the 
larger comparative effectiveness review on SGAD. We screened 1,532 full text articles 
for eligibility; of these, 63 studies of low and moderate risk of bias (58 RCTs, five 
observational studies) reporting data on any sexual dysfunction outcome or adverse 
event met our inclusion criteria for analysis. The majority of experimental trials were of 
six to eight weeks in duration.  
 
Adverse events reporting and determination of sexual dysfunction varied widely among 
studies. Specific methods included prospective, systematically monitored and validated 
instruments to measure sexual function, rating scales, or structured clinical interviews 
to diagnose sexual dysfunction. Additionally, study authors relied on adverse events 
gathered by spontaneous patient reports, or using open questions or generic checklists 
by clinicians. In 22 of 58 (37.9%) RCTs, study authors did not provide any information 
on the method to collect adverse event data or determine sexual dysfunction. Only 14 of 
58 (24.1%) RCTs reporting sexual dysfunction outcomes or adverse events reported a 
specific method to determine adverse events or outcomes of sexual dysfunction. In 
seven of 16 RCTs, study authors used a standardized validated instrument to establish 
sexual dysfunction at baseline and during the study period; however, they did not 
provide sufficient data in the published article to calculate sexual dysfunction outcomes.  
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All of the observational studies with data on sexual function outcomes reported the 
method to ascertain sexual dysfunction or adverse event; three of the five used a 
validated sexual function instrument (the Changes in Sexual Functioning Questionnaire; 
the Arizona Sexual Experience Scale; the Psychotropic-Related Sexual Dysfunction 
Questionnaire). 
3.1. Evidence of risk of sexual dysfunction in patients with MDD from 
RCTs 
Our analyses (quantitative or descriptive) included 58 RCTs of low or moderate risk of 
bias with information on sexual dysfunction, representing approximately 19,000 
patients treated with SGAD.  
3.1.1. Network meta-analysis 
We conducted network meta-analyses of adverse events of sexual dysfunction using 
data from placebo-controlled or head-to-head trials. Of the 58 RCTs fulfilling the study 
eligibility criteria we could finally include 37 RCTs [26-62] meeting the statistical 
requirements for network meta-analysis. Overall, 14,576 patients were randomly 
assigned to placebo or one of the eleven included SGAD drugs. Twenty-two studies were 
two-arm trials, eleven were three-arm trials involving two different active comparisons 
and placebo, and four were multi-arm trials involving two or more active compounds at 
various dosages and placebo. The network of all included pairwise comparisons is 
shown in Fig. 2. 
 
The full model random effects network meta-analysis included 66 pairwise comparisons 
(55 active SGAD pairwise comparisons and 11 placebo-controlled comparisons). We 
found statistically significant differences in adverse events of sexual dysfunction in 14 of 
the pairwise active comparisons (Table 1). Most comparisons showed a similar risk of 
sexual dysfunction among included SGAD; however, credible intervals were wide and 
included differences that would be considered clinically relevant. Eight individual 
comparisons present a statistically significantly higher risk of sexual dysfunction of one 
drug over another.  
 
Nevertheless, three main patterns emerged (see Fig. 3): (1) Bupropion had a statistically 
significantly lower risk of sexual dysfunction than some other SGAD (escitalopram, 
paroxetine, and sertraline). (2) Escitalopram showed a statistically significantly higher 
risk of sexual dysfunction than some other SGAD (fluoxetine, mirtazapine, and 
nefazodone). (3) Paroxetine had a statistically significantly higher risk of sexual 
dysfunction than some other SGAD (fluoxetine, mirtazapine, nefazodone, and 
venlafaxine). 
 
Convergence was satisfied in the full model, but not fully satisfactory for citalopram-
comparisons in the model including only trials where sexual dysfunction was 
spontaneously reported by patients or elicited by open question. Findings of the 
sensitivity analyses assessing the impact of the method used to determine sexual 
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dysfunction in the network meta-analysis model were somewhat conflicting in that 
consistency between the different reporting methods could not always be confirmed.  
 
Because of the indirect nature of the comparisons, the often wide credible intervals, and 
the high variation in magnitude of outcome, we rated the overall strength of evidence 
with respect to our findings low. 
3.1.2. Descriptive analysis using data of trials reporting only sex-specific 
rates of sexual dysfunction  
Due to reasons of heterogeneity, we did not combine direct and indirect evidence for 
pairwise comparisons from the trials reporting only sex-specific incidence of sexual 
dysfunction. Instead, we performed descriptive analysis calculating weighted mean 
rates pooling data both from active comparator and placebo-controlled trials. Overall, 
we used data from 21 RCTs [63-83] providing sex-specific rates of sexual dysfunction 
from 4,159 patients including six different SGAD (44 study arms: 34 active arms, 10 
placebo-controlled arms).  
 
We analyzed sex-specific rates separately and required a minimum of two trials to 
calculate weighted mean rates (WMR). Only trials reporting male-specific rates of sexual 
dysfunction provided sufficient data to allow calculation of WMR. Figure 4 summarizes 
by specific drug, the WMR of sexual dysfunction based on male-specific rates and 95 
percent confidence intervals (95% CI) in patients with MDD reported in RCTs of SGAD. 
Across all trials reporting male-specific rates, the WMR of sexual dysfunction was 12.3 
percent (95% CI 8.8 to 15.8), with a range of 8.8 percent of sexual dysfunction for 
fluoxetine (95% CI 0.5 to 17.0) and 15.8 percent for sertraline (95% CI 1.2 to 30.4). 
Overall, rates of sexual dysfunction did not differ among duloxetine, escitalopram, 
fluoxetine, paroxetine, sertraline, and venlafaxine.  
3.2. Evidence of sexual dysfunction in patients with MDD from 
observational studies 
Descriptive analysis of tolerability used data from almost 7,200 study participants using 
SGAD (with a total of n=10 different drugs). We were able to include five observational 
studies providing data on sexual dysfunction: three prospective cohort studies [14, 84, 
85], one prescription-event monitoring database study, [86] and one cross-sectional 
survey [87]. Except for the study by Mackay and co-authors [86] and the one by Meijer 
and colleagues [84], standardized validated instruments to ascertain sexual dysfunction 
at baseline and throughout follow-up were used. All of the five studies were conducted 
in various international outpatient settings. We present crude rates and incidence 
density rates of individual studies separately. 
 
Table 2 summarizes, by specific drug, the incidence and prevalence of sexual 
dysfunction reported in three prospective cohort studies of SGAD in patients with MDD. 
Due to differences in study design and patient follow-up we did not calculate pooled 
weighted mean rates. Instead, rates from the individual studies are shown. In two of 
these prospective studies [14, 85] incidence rates at six months of follow-up were used. 
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The rates reported by Clayton et al. [87] refer to prevalence data from a cross-sectional 
study using data of a subsample of patients free of other possible causes of sexual 
dysfunction, yet with a wide range of treatment duration. 
 
Rates of sexual dysfunction tended to be higher than those reported in RCTs. Overall, the 
weighted mean incidence of sexual dysfunction across all observational studies was 40.4 
percent (95% CI 28.3% to 52.6%). Reported rates by specific drug ranged from 7.0 
percent prevalence for bupropion in a cross-sectional study [87] to a 72.7 percent six-
month-incidence for citalopram in a prospective cohort study [14]. Both studies relied 
on validated instruments to ascertain sexual function, although only the study by 
Montejo et al. established a cohort free of sexual dysfunction at the outset [14]. Six-
month-incidence rates tended to be higher than the prevalence rates gathered from the 
cross-sectional survey (citalopram 72.7% vs. 30.0%, fluoxetine 57.7% vs. 23.0%, 
paroxetine 70.7% vs. 25.0%, sertraline 62.9% vs. 25.0%, and venlafaxine 67.3% vs. 
30.0%, respectively). Duenas et al. reported a six-month incidence rate of 23.4% for 
duloxetine in outpatients from a prospective cohort study including only sexually active 
patients without sexual dysfunction at study enrolment [85]. 
 
Due to differences in study design, rates of sexual dysfunction from two additional 
observational studies could not be pooled with the ones from the above mentioned 
three prospective cohort studies. Incidence density rates, which adjust for time of 
exposure, reported in the individual studies were converted and are shown in table 3. 
From a prescription-event monitoring database study [86], adverse events of only male 
sexual dysfunction (impotence or ejaculation failure) were recorded showing a rate of 
9.6 per 1000 person-years for nefazodone, and 30 per 1000 person-years for 
paroxetine. Sexual dysfunction adverse events for sertraline in a prospective 
observational study [84] were reported as number of first adverse events per 1000 
person-years, yet study authors did not ascertain participants' baseline status of sexual 
function prior to antidepressant medication. Patients were followed for an average 
duration of 5.7 months (range one to 365 days). Reported rates were higher for men 
than for women (loss of libido 31/1000 person-years; ejaculation failure 14/1000 
person-years; impotence 9/1000 person-years; other male sexual function disorder 
4/1000 person-years; female anorgasmia 6/1000 person-years; other female sexual 
function disorder 3/1000 person-years). 
4. Discussion 
In this systematic review with data from sixty-three studies of low and moderate risk of 
bias (58 RCTs, five observational studies) with more than 26,000 patients treated with 
SGAD, we found some variation in sexual dysfunction associated with SGAD across 
drugs, yet no consistent differences between drugs. The methods used to assess adverse 
events varied considerably in efficacy trials with about a third of the trials included in 
our analysis providing no information on how harms-related data was collected or how 
sexual function was assessed, and only a fifth of the trials using a specific method or 
instrument to determine sexual dysfunction. We rated the overall strength of evidence 
low, indicating a low confidence that the evidence reflects the true effect.  
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In our network meta-analyses, most comparisons showed a similar risk of sexual 
dysfunction among included SGAD. Credible intervals, however, were wide and included 
differences that would be considered clinically relevant. Since we conducted multiple 
comparisons and found differences in the method sexual dysfunction was defined and 
reported in individual trials, these results should be interpreted cautiously. 
Nevertheless, we observed three main patterns: Bupropion had a statistically 
significantly lower risk of sexual dysfunction than some other SGAD, and both 
escitalopram, and paroxetine showed a statistically significantly higher risk of sexual 
dysfunction than some other SGAD. 
 
Our findings of varying rates of adverse events are consistent with previous studies. 
Authors of a systematic review and meta-analysis using data from 234 studies with 
direct and indirect comparisons of SGAD found no substantial differences in efficacy for 
the treatment of MDD, however, differences were found with respect to onset of action, 
frequency of adverse events and rates of discontinuation [11]. With respect to the 
observed lower risk of sexual dysfunction for bupropion, our findings are consistent 
with a previous systematic review and meta-analysis comparing sexual adverse events 
of bupropion and three SSRIs (fluoxetine, paroxetine, sertraline) which found bupropion 
causing significantly less sexual dysfunction than the comparator drugs while having 
similar effectiveness [15], a finding that was later replicated in a US-cross-sectional 
study [87] and by authors of a comparative effectiveness review and meta-analysis [11]. 
That patients treated with bupropion experience less frequent treatment-emergent 
sexual dysfunction has been explained with the lack of serotonergic activity of this drug 
(a selective norepinephrine and dopamine reuptake inhibitor). We found mirtazapine to 
be associated with a lower risk of sexual dysfunction in some pairwise comparisons. 
Mirtazapine, classified a noradrenergic and specific serotonergic antidepressant, has 
been described to have minimum effects on monoamine reuptake and was shown to be 
less likely associated with sexual adverse events compared to SSRIs (fluoxetine, 
paroxetine, sertraline) [17]. 
 
As to the results of the descriptive analyses, we cannot draw firm conclusions about the 
comparative harms of second-generation antidepressants. Using data from all trials 
reporting male-specific rates, rates of sexual dysfunction did not differ among included 
SGAD. We observed lower rates of sexual dysfunction across trials reporting only sex-
specific rates as compared to those reported in observational studies. Underscoring the 
validity of the estimate of sexual dysfunction associated with antidepressants reported 
in observational studies is the use of prospectively defined populations free from sexual 
dysfunction at baseline and the prospective assessment of sexual function with 
standardized and validated instruments. Conversely, the majority of the efficacy trials 
included in our analysis did not include such study procedures, thus making it difficult 
to establish treatment-emergent sexual dysfunction. 
 
We found reporting of adverse events related to sexual dysfunction in some of the RCTs 
included in our analysis inconsistent and insufficient. In the majority of trials, 
investigators did not specify how harms-related information was gathered: definitions 
of adverse events of sexual dysfunction were often not explicit and clear; also, 
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investigators sometimes relied on scales to assess sexual function that lacked 
appropriate instrument development and validation. Additionally, authors often did not 
state the time frame of surveillance for adverse events thus not specifying whether 
recording of adverse events occurred retrospectively or prospectively; also, only 
collecting data on adverse event for some time after the study intervention can capture 
longer latency. Only rarely did authors provide information on reasons for 
discontinuations and withdrawals due to adverse events. In none of the included RCTs 
did authors report on whether attribution of a specific cause was blinded to the assigned 
treatment. Also, it was difficult to establish from the data of the individual studies 
whether or how study investigators combined data for different subsets of sexual 
dysfunction adverse events into one outcome measure. Also, sexual dysfunction as a 
harm of second-generation antidepressant treatment was chosen as a major primary 
outcome in only a minority of included studies and authors did not describe a-priori 
plan of statistical analysis. Problems of low power for uncommon events or adjustment 
for multiple outcomes were not addressed. Due to these shortcomings by investigators 
of individual trials included in our analysis, comparison of rates of sexual dysfunction, 
particularly from efficacy trials, must be made with great caution.  
 
Our study has several limitations. Selection of studies was limited to English-language 
publications only. We did not account for observed differences in medication dosages, 
study duration or any confounding from use of concomitant medications or comorbid 
conditions potentially affecting sexual function. The majority of included RCTs were of 
short duration so that an estimation of long-term effects of treatment-emergent sexual 
dysfunction is not possible. Also, we included RCTs that did not report any baseline 
assessment of sexual dysfunction. Thus, the reported rates sexual dysfunction in these 
trials might have been inflated. Furthermore, only a small number of trials included in 
the network meta-analysis reported sex-specific rates so we did not perform sex-
specific analyses. Although type, severity and clinical course of sexual dysfunction 
associated with antidepressant treatment can vary by gender [88], we were not able to 
assess the potential impact of gender on estimated sexual dysfunction adverse events. 
Results of both the network meta-analyses and the descriptive analyses should 
therefore be interpreted with caution. Network meta-analysis is a method that combines 
direct and indirect information across a network of RCTs and provides estimates of the 
(adverse) effect of each intervention relative to each other, whether or not they have 
been directly compared in trials, yet the key assumption is consistency between direct 
and indirect estimates of effect [89]. We cannot completely rule out that observed 
differences across trials might be due to violations of consistency assumptions. Still, in 
the absence of sufficient head-to-head evidence, network meta-analysis can serve as an 
additional tool to synthesize multiple treatments.  
 
The onset of treatment-emergent sexual dysfunction or aggravation of a preexisting 
sexual dysfunction may add to the distress of a patient with MDD, diminish the patient's 
quality of life, lead to the discontinuation of antidepressant treatment and also threaten 
the doctor-patient relationship, particularly if the patient has not been fully informed of 
such adverse events of second-generation antidepressants [90]. Since evidence suggests 
that SGAD largely have similar efficacy, onset of action and specific adverse events 
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profiles should guide a clinician's choice of a specific drug for an individual patient. 
Given the impact of sexual dysfunction on a patient's quality of life, clinicians should 
provide patients with all relevant information on possible sexual adverse events of a 
particular antidepressant and discuss patients' preferences and values before initiating 
antidepressant therapy. If patients are concerned about maintaining normal sexual 
functioning (e.g. younger patients), the decision of choosing an antidepressant that is 
less likely to be associated with sexual dysfunction should be discussed.  
5. Conclusions 
Based on the findings of this review using data from RCTs and observational studies on 
adverse events and second-generation antidepressants, the comparative risk of sexual 
dysfunction associated with a specific antidepressant cannot be precisely determined. 
Nevertheless, we observed three main patterns in our network meta-analysis with 
bupropion having a statistically significantly lower risk of sexual dysfunction than some 
other SGAD, and both escitalopram, and paroxetine showing a statistically significantly 
higher risk of sexual dysfunction than some other SGAD. Clinicians should routinely 
discuss the possibility of sexual dysfunction as adverse events of second-generation 
antidepressants and take into account patients’ preferences when selecting an 
antidepressant and monitoring treatment. Further, we found inconsistencies and 
shortcomings in methods to determine and report adverse events of sexual dysfunction 
in many of the studies included in this review, thus potentially contributing to biased 
estimates. Future studies on SGAD should be adequately powered to provide complete, 
reliable, accurate and gender-specific information on adverse events and should be 
designed and conducted using systematic and valid methods to assess sexual 
dysfunction adverse events. Also, reporting quality of adverse events of sexual 
dysfunction in published trials should be improved to help researchers better appraise 
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*RCTs were included in the network meta-analysis if they fulfilled (i) general study eligibility criteria, and (ii) statistical 
requirements for network meta-analysis. RCTs randomized controlled trials 
  
7,039 records identified through 
database searching 
167 of additional records identified 
through other sources 
7,206 records identified (4,476 records after duplicates 
removed) 
4,476 abstracts screened 2,944 of records excluded 
1,532 of full-text articles assessed 
for eligibility 
 
63 studies included in 
qualitative analysis  
1,469 of full-text articles excluded:  
 
Wrong outcome or data not sufficient to 
calculate rate of sexual dysfunction 
(n=402) 
Wrong drug (n=146) 
Wrong publication type (n=265) 
Wrong study design (n=481) 
Duration too short (n=11) 
Wrong population (n=88) 
Wrong language (n=8) 
High risk of bias (n=63) 
Article with study already included (n=5) 


































Fig. 2 Network of all included comparisons for the network meta-analysis of 





IR: immediate release; XR: extended release 
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Fig. 3 Results of network meta-analysis of sexual dysfunction for selected pairwise 




   Higher rate of SD for first drug**  Higher rate of SD for second drug*  
_____________________________________________________________________________________________________ 
* Odds ratios <1 indicate a higher rate of sexual dysfunction of the drug listed on the left-hand side ('first drug'); ** Odds 
ratios >1indicate a higher rate of sexual dysfunction of the drug listed on the right-hand side ('second drug'); selected 









Data are presented as % (95 % confidence intervals). Weighted mean rates (%) calculated using drug-specific rates of 
sexual dysfunction from individual randomized controlled trials pooling data from active-comparator trials and placebo-
controlled trials. Rates were calculated only if data from at least two trials were available (only male-specific rates could 
be calculated; we did not use data from a small RCT for desvenlafaxine and trazodone, respectively). Comparisons across 
drugs must be made cautiously: method and extent of adverse event assessment differed across studies.  
  
Forest (meta-analysis) plot from Book 1
0 10 20 30 40
Venlafaxine 12.30 (1.40, 23.20)
Sertraline 15.80 (1.20, 30.40)
Paroxetine 15.10 (2.30, 27.90)
Fluoxetine 8.80 (0.50, 17.00)
Escitalopram 9.30 (1.90, 16.60)
Duloxetine 10.80 (2.20, 19.50)
Fig. 4 Male-specific weighted mean rates of sexual dysfunction from individual 
randomized contr lled tri ls 
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Table 1  Odds ratio of sexual dysfunction (95 % credible intervals for pairwise 
comparisons, mixed-treatment comparison)a        
Pairwise comparisons  OR of sexual 
dysfunctiona 
(95% CrI) 
Bupropion vs. Citalopram 2.94  (0.81-7.90) 
Bupropion vs. Duloxetine 2.21 (0.88-4.67) 
Bupropion vs. Escitalopram 3.08 (1.27-6.45) 
Bupropion vs. Fluoxetine 1.02 (0.42-2.11) 
Bupropion vs. Fluvoxamine 1.35 (0.24-4.44) 
Bupropion vs. Mirtazapine 0.82 (0.20-2.29) 
Bupropion vs. Nefazodone 0.45 (0.10-1.29) 
Bupropion vs. Paroxetine 3.56 (1.45-7.38) 
Bupropion vs. Sertraline 2.21 (1.07-4.12) 
Bupropion vs. Venlafaxine 1.30 (0.47-2.93) 
Citalopram vs. Duloxetine 0.96 (0.26-2.51) 
Citalopram vs. Escitalopram 1.31 (0.41-3.15) 
Citalopram vs. Fluoxetine 0.46 (0.11-1.30) 
Citalopram vs. Fluvoxamine 0.59 (0.08-2.16) 
Citalopram vs. Mirtazapine 0.36 (0.06-1.17) 
Citalopram vs. Nefazodone 0.20 (0.03-0.66) 
Citalopram vs. Paroxetine 1.57 (0.41-4.13) 
Citalopram vs. Sertraline 0.96 (0.30-2.32) 
Citalopram vs. Venlafaxine 0.57 (0.14-1.60) 
Duloxetine vs. Escitalopram 1.50 (0.68-2.93) 
Duloxetine vs. Fluoxetine 0.52 (0.18-1.18) 
Duloxetine vs. Fluvoxamine 0.67 (0.12-2.17) 
Duloxetine vs. Mirtazapine 0.41 (0.10-1.13) 
Duloxetine vs. Nefazodone 0.22 (0.05-0.64) 
Duloxetine vs. Paroxetine 1.72 (0.81-3.20) 
Duloxetine vs. Sertraline 1.11 (0.48-2.25) 
Duloxetine vs. Venlafaxine 0.65 (0.22-1.51) 
Escitalopram vs. Fluoxetine 0.37 (0.13-0.85) 
Escitalopram vs. Fluvoxamine 0.48 (0.08-1.58) 
Escitalopram vs. Mirtazapine 0.29 (0.07-0.82) 
Escitalopram vs. Nefazodone 0.16 (0.03-0.46) 
Escitalopram vs. Paroxetine 1.26 (0.50-2.58) 
Escitalopram vs. Sertraline 0.79 (0.39-1.54) 
Escitalopram vs. Venlafaxine 0.47 (0.16-1.08) 
Fluoxetine vs. Fluvoxamine 1.49 (0.24-5.07) 
Fluoxetine vs. Mirtazapine 0.89 (0.20-2.60) 
Fluoxetine vs. Nefazodone 0.49 (0.10-1.50) 
Fluoxetine vs. Paroxetine 3.86 (1.44-8.40) 
Fluoxetine vs. Sertraline 2.44 (0.94-5.26) 
Fluoxetine vs. Venlafaxine 1.41 (0.47-3.30) 
Fluvoxamine vs. Mirtazapine 0.96 (0.12-3.60) 
Fluvoxamine vs. Nefazodone 0.52 (0.06-2.01) 
Fluvoxamine vs. Paroxetine 4.08 (0.81-12.73) 
Fluvoxamine vs. Sertraline 2.59 (0.53-7.98) 
Fluvoxamine vs. Venlafaxine 1.54 (0.25-5.29) 
Mirtazapine vs. Nefazodone 0.73 (0.11-2.56) 
Mirtazapine vs. Paroxetine 5.73 (1.55-15.29) 
Mirtazapine vs. Sertraline 3.62 (1.01-9.59) 
Mirtazapine vs. Venlafaxine 2.03 (0.57-5.31) 
Nefazodone vs. Paroxetine 10.98 (2.69-30.96) 
Nefazodone vs. Sertraline 6.89 (1.81-18.89) 
Nefazodone vs. Venlafaxine 4.11 (0.84-12.70) 
Paroxetine vs. Sertraline 0.68 (0.30-1.35) 
Paroxetine vs. Venlafaxine 0.40 (0.14-0.89) 
Sertraline vs. Venlafaxine 0.61 (0.25-1.24) 
a Relative treatment effect of each treatment relative to reference comparator expressed as OR (with 95 % CrI). An OR <1 
indicates a higher rate of SD of the drug listed on the left-hand side (‘first drug’); an OR >1 indicates a higher rate of SD of 
the drug listed on the right-hand side (‘second drug’). Method and extent of adverse event assessment differed across 
studies; comparisons across drugs must be made cautiously. Based on random-effects network meta-analysis using 
Bayesian methods. CrI credible interval, OR odds ratio, SD sexual dysfunction 
 18 
 
Table 2  Prevalence/Incidence of sexual dysfunction from three observational 
studies (crude rates as percentages from individual studies)  
Drug Sexual dysfunction 
(mean percentage) 
Study design N included in analysis 
Bupropion 7.0 cross-sectional surveya 45 
Citalopram 30.0 cross-sectional surveya 83 
72.7 prospective studyb 66 
Duloxetine 23.4 prospective studyc 406 
Fluoxetine 23.0 cross-sectional surveya 245 
57.7 prospective studyb 279 
Fluvoxamine 62.3 prospective studyb 77 
Mirtazapine 24.4 prospective studyb 49 
Nefazodone 8.0 prospective studyb 50 
Paroxetine 25.0 cross-sectional surveya 159 
70.7 prospective studyb 208 
Sertraline 
25.0 cross-sectional surveya 161 
62.9 prospective studyb 159 
Venlafaxine 30.0 cross-sectional surveya 70 
 67.3 prospective studyb 55 
MDD major depressive disorder, SD sexual dysfunction, 
a Prevalence rates; patients with MDD; subsample with patients free of other possible causes of SD; length of treatment 
varied (1% < a week; 24% more than a week but less than 3 months; 17% more than 6 months but less than 12 months; 
28% one to three years; 12% more than 3 years);[87]  
b Incidence rates calculated at 6 months of follow-up in participants free of SD prior to antidepressant medication;[14]  
c Incidence rates calculated at 6 months of follow-up in sexually active patients without SD at study enrolment;[85] 
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Table 3  Incidence density rate of sexual dysfunction from two observational 
studies  
Drug Sexual dysfunction (incidence 
density rates) 
Study design N included in 
analysis 
Nefazodone 9.6/1000 PY prescription-event monitoring, 
database studya; only male SD 
(impotence or ejaculation 
failure), 1 study 
4418 
Paroxetine 30/1000 PY prescription-event monitoring, 
database studya; only male SD 
(impotence or ejaculation 
failure), 1 study 
4373 
Sertraline loss of libido 31/1000 PY; 
ejaculation failure 14/1000 PY; 
impotence 9/1000 PY; other 
sexual function disorder (male) 
4/1000 PY; anorgasmia 
(female) 6/1000 PY;  other 
sexual function disorder 
(female) 3/1000 PY  
prospective observational 
studyb, 1 study 
659 
PY person years, SD sexual dysfunction 
a Unclear whether study participants were free of SD prior to antidepressant medication; SD recorded in patients record 
after the date of first prescription;[86]  
b Unclear whether study participants were free of SD prior to antidepressant medication; SD adverse events were 
ascertained by open question by clinician; start and stop dates of the events and assessment of severity (‘mild’, ‘moderate’ 
or ‘severe’) were recorded; patients were followed for an average duration of 5.7 months (range 1–365 days)[84] 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author, Year 
Alvarez et al, 2012 [1] 




H. Lundbeck A/S 
 
Research objective 
To evaluate efficacy, 
safety, and tolerability 
of Lu AA21004 vs. 
placebo using 
venlafaxine XR as 
active reference in 
patients with DSM-IV-
TR major depressive 
disorder (MDD) 
Drugs, Doses, and 
Range 
D1: PBO 
D2: VENLA XR (225 







phase II RCT, double 
blinded 
Duration 
6 weeks  




D2: Venlafaxine XR 
 
Inclusion criteria: 
 Adults (age range): 
18-65 years  
 Diagnosed with 
MDD according to 
DSM-III or -IV: 
Current epidsode 
of MDD with at 
least 3 months' 
duration 
 MADRS: total 







 current or past 











or mental disorders 
due to a general 
medical condition 
 Patients at serious 
risk of suicide, 
based on the 
Groups similar at 
baseline 
Yes 








Sex, % female 
D1: 65.7 
D2: 54.9 













D1: 2/105 (1.9%) 
D2: n=3 of women 
reported AE related 
to SD (3/62, 4.8% of 
women); n=11 of men 
reported AE related 
to SD (11/51, 21.6% 
of men); overall % 
with SD 14/114 
(12.3%); #AE 
reported: anorgasmia 
7/51(13.7% of men); 
ejaculation delayed 
4/51 (7.8% of men);  
erectile dysfunction 
4/51 (7.8% of men); 2 
withdrawals due to 
SD (1 anorgasmia,1 
delayed ejaculation); 
non-leading question 
to ascertain AE; no 
targeted questions/ 
no specific instrument  
used to assess SD 
Risk of Bias: 
low 
Withdrawals due to 
adverse events, % 
D1: 4 
D2: 14 
Withdrawals due to 
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Method used to 
determine SD 
Analysis and Study 




or who had a score 
of 5 on item 10 of 
the MADRS scale 
(suicidal thoughts) 
 any substance 
abuse disorder 
within the previous 
6 months, 
 presence or history 







 any Axis II disorder 
that might 
compromise their 




 Adverse events 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 







H. Lundbeck A/S 
 
Research objective 
To evaluate short- and 
long-term 
antidepressant 
tolerability and efficacy 
of ESC and PAR. 
Drugs, Doses, and 
Range 
D1: ESC (10-20 mg 1 x 
daily): low-high; 
10-20 mg 












8 weeks (includes both 
acute and 
maintainence periods) 







 Adults (age range): 
18 years old and 
over 
 Diagnosed with 
MDD according to 
DSM-III or -IV: 
Current epidsode of 
MDD 
 MADRS: 22 or 
























 Investigational drug 
use within last 3 
months 
 MADRS item 10 
score of 5 or greater 
Groups similar at 
baseline 
Yes 
































ASEX scores, week 
27%:  
D1: 57.7 (proportion of 
patients with sexual 
dysfunction (LOCF 
analysis) declined 
from baseline (67.3%) 
during both acute 
(61.2% at week 8) and 
maintenance 
treatment) 
D2: 57.0 (proportion of 
patients with sexual 
dysfunction (LOCF 
analysis) declined 
from baseline (69.9%) 
during both acute 





Overall attrition, %:  
28 
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 Another Axis I 
disorder within 
previous 6 months 
 Learning disability 
 Cognitive disorder 
 Nonresponse or 
hypersensitivity to 
CIT and/or PAR 
 History of severe 
allergy or 
hypersensitivity 
 History of lactose 
intolerance 
 Antidepressants 
within 2 weeks 
before screening 
 Triptans, oral 
anticoagulants 
 Sildenafil citrate 
 Cimetidine 
 Type 1c anti-
arrhythmics 
 Cardiac glycosides 
 Narcotic analgesics 




 Adverse events 
 Quality of life 
scales, ASEX scale 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author, Year 
Baldwin et al., 2012 
[3] 




H. Lundbeck A/S 
 
Research objective 
To evaluate efficacy, 
safety, and tolerability 
of Lu AA21004 
versus placebo, using 
duloxetine as active 





Drugs, Doses, and 
Range 
D1: PBO 









RCT, double blinded 
Duration 
8 weeks  







 Adults (age range): 
18-75 years  
 Diagnosed with 
MDD according to 
DSM-III or -IV: 
Current epidsode 
of MDD with at 
least 3 months' 
duration 
 MADRS: total 
score ≥26 at both 







 current or past 











or mental disorders 
due to a general 
medical condition 
 Patients at serious 
risk of suicide, 
based on the 
investigator’s 
Groups similar at 
baseline 
Yes 
n =  
D1: 152 
D2: 157  
Overall: 309 




Sex, % female 
D1: 69.6 
D2: 67.7 




























(13.5% of men) 
non-leading question 
to ascertain AE; no 
targeted questions/ 
no specific instrument  




Risk of Bias: 
Moderate 
Withdrawals due to 
adverse events, % 
D1: 8 
D2: 11 
Withdrawals due to 




Sexual Dysfunction associated with Second-Generation Antidepressants in Patients with Major Depressive Disorder - Results from a Systematic Review with Network Meta-Analysis. 
Drug Safety; U. Reichenpfader, G. Gartlehner, L.C. Morgan, A. Greenblatt, B. Nussbaumer, R. A. Hansen, M. Van Noord, L. Lux, and B. N. Gaynes. Corresponding author: 
 
U. 
Reichenpfader, Department for Evidence-based Medicine and Clinical Epidemiology, Krems, Austria; Department of Medical and Health Sciences - Division of Community Medicine, 















Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
clinical judgement, 
or who had a score 
of 5 on item 10 of 
the MADRS scale 
(suicidal thoughts) 
 any substance 
abuse disorder 
within the previous 
6 months, 
 presence or history 







 any Axis II disorder 
that might 
compromise their 




 Adverse events 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 










To compare onset of 
antidepressant efficacy 
of MIR and SER 




Overall study N: 
346 
Intervention: 
D1: MIR: 30-45 mg/d 
D2: SER: 50-150 mg/d 
Inclusion criteria: 
 Adults 18 to 70 
 Diagnosed with 
MDD according to 
DSM-III or -IV 
 Minimum HAM-D 








 Additional mental 
illnesses or organic 
mental disorder  
 Illicit drug and 
alcohol abuse 
 Clinically sig 
medical disease 
 Suicidal tendencies  
 Epilepsy 











Mean age (yrs): 
D1: 42 
D2: 41  
Sex (% female): 
D1: 55.7 
D2: 61.5  




Mean HAM-D score 
at baseline: 
NR 
 CSFQ data not 
shown; AE: decrease: 
D1 1.1% 
D2: 5.9% 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 












Safety and efficacy of 
MIR and PAR in 
treatment of major 
depression 




Overall study N: 
275 
Intervention: 
D1: MIR: 15-45 mg/d 
(32.7) 
D2: PAR: 20-40 mg/d 
(22.9) 
Inclusion criteria: 
 Adults 18 to 70 
 Diagnosed with 
MDD according to 
DSM-III or -IV 
 Minimum HAM-D 
score of 18 
Exclusion criteria: 
 Pregnant 
 Additional mental 
illnesses or organic 
mental disorder  
 Suicidal tendencies  
 
Mean age (yrs): 
D1: 47.2 
D2: 47.3  
Sex (% female): 
D1: 63 
D2: 65  




Mean HAM-D score 
at baseline: 
D1: 22.4 (3.3) 
D2: 22.4 (3.2) 
 
D1: orgasmic 
dysfunction 3.1%  
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 











To compare SER and 
FLUOX in outpatients 
with depression 




Overall study N: 
286 
Intervention: 
D1: SER: 50-100 mg/d 




 Adults 18 or older 
 Diagnosed with 
MDD according to 
DSM-III or -IV 
 Minimum HAM-D 




 Additional mental 
illnesses or organic 
mental disorder  
 Illicit drug and 
alcohol abuse 
 Suicidal tendencies  
 
Mean age (yrs): 
D1: 49.9 
D2: 49.9  
Sex (% female): 
D1: 57.7 
D2: 64.6  













libido): 3/60 (5% of 
men) 
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Method used to 
determine SD 
Analysis and Risk 
of Bias 
Author: 












To compare ESC and 
VEN XR in depressed 
outpatients at highest 
recommended doses in 
United States 




Overall study N: 
198 
Intervention: 
D1: ESC: 20mg 
D2: VEN: XR 225mg 
Inclusion criteria: 
 Adults 18 to 65  
 Diagnosed with 
MDD according to 
DSM-III or -IV 
 HAM-D24 > 20 
 Normal physical 
exam, labs, and 
ECG (or any 
abnormality 
insignficant) 








 Additional mental 
illnesses or organic 
mental  
 Illicit drug and 
alcohol abuse 
 Clinically sig 
medical disease 
 Suicidal tendencies  
 Previous treatment 
with VEN or ESC 
 Failure to respond 
to adequate trials of 
2+ antidepressants 
Mean age (yrs): 
D1: 37.3 
D2: 37.5  
Sex (% female): 
D1: 69.4 
D2: 47.0  
Race (% white): 
D1: 77.6 
D2: 73.0  
Baseline (HAM-A): 
NR 
Mean HAM-D score 
at baseline: 
D1: 28.6 (4.1) 
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Method used to 
determine SD 
Analysis and Study 
















To compare efficacy and 
tolerability of ESC (20 
mg/day) and PAR (40 
mg/day) in patients with 
severe MDD over a 
treatment period of 24 
weeks and to investigate 
if treatment outcome for 
severely depressed 
patients depends on 
their baseline level of 
anxiety. 
Drugs, Doses, and 
Range 
D1: ESC (10-20 mg 1 x 
daily): 20 mg 1 x 
daily; high 
D2: PAR (10-60 mg 1 x 
















 Adults (age range): 
18 to 75 years 
 Diagnosed with 
MDD according to 
DSM-III or -IV 
 MADRS: score 
greater than or 
equal 30 at 
baseline 
 Duration of 
depressive episode 
had to be more 
than 2 wks, but less 





















cognitive disorder  
 Illicit drug and 
alcohol abuse: 
Groups similar at 
baseline 
Yes 




analysis of highly 
anxious patients: 
n=286) 
Mean age, years 
D1: 43.8 (12.5) 
D2: 44.7 (13.0) 
Sex, % female 
D1: 67 
D2: 70 




D1: 23.5 (7.5) 












MADRS total score 
D1: 8% of men; 
erectile dysfunction 
(men):  n=4 (of 153 
with AE; (5.3% of 
men); ejaculation 
delayed (men),  n=2 ( 
2.7% of men) 
 
D2: 14.7% of men 
(ns); erectile 
dysfunction (men): 
paroxetine n=4 (of 
162 with AE; 5.9% of 
men); escitalopram: 
n=4 (of 153 with AE; 
(5.3% of men); 
ejaculation delayed 
(men): paroxetine n=6 
(of 162 with AE; 8.8% 
of men), escitalopram: 
n=2 (of 153 with AE; 












Overall attrition, %:  
26.3 % attrition rate 
based on number of 
patients randomized, 
n= 459. 
Attrition rate, %:  
D1: 20,3 
D2: 32,6 
Withdrawals due to 
adverse events, % 
D1: 7.8 
D2: 15.4 
Withdrawals due to 




The calculations were 
based on number of 
patients randomized 
(Overall n= 459; ESC 
20 mg/day n= 232, 
PAR 40 mg/day n= 
227).  
Significantly more 
patients (P < 0.01) 
withdrew from PAR 
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D1: ESC 20 mg/day 
D2: PAR 40 mg/day 
 
within 12 months  
 ECT within last: 6 
months 
 Suicidal tendencies 
 History of lactose 
intolerance 
 History of 
hypersensitivity or 
non-response to 
CIT, ESC or PAR.  
 Score ≥ 5 on item 
10 of MADRS scale 







 MADRS: total score 
mean change from 
baseline to week 24 
 CGI-S or CGI-I 
 Quality of life scales 
 HAM-A 
was approximately 35 
in both treatment 
groups, indicating a 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 












To evaluate efficacy 
and tolerability of ESC 
in treatment of MDD 








D2: ESC 10 mg/d 
D3: ESC 20 mg/d 
D4: CIT 40 mg/d 
 
Inclusion criteria: 
 Adults 18 to 65  
 Diagnosed with 
MDD according to 
DSM-III or -IV 
 Minimum HAM-D 
score of at least 2 
on item 1 
(depressed mood) 
 Depressive episode 
≥ 4 wks 








 Illicit drug and 
alcohol abuse 
 Suicidal tendencies  
 Any DSM-IV Axis I 
disorder other than 
MDD 
 Score at least 5 on 
item 10 of MADRS 














Mean HAM-D score 
at baseline: 
D1: 25.8 (5.9) 
D2: 24.3 (6.2) 
D3: 25.8 (5.7) 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 













anxiolytic efficacy of 
PAR and FLUOX in 
patients with major 
depression 




Overall study N: 
203 
Intervention: 
D1: PAR: 20-50 mg/d 




 Diagnosed with 
MDD according to 
DSM-III or -IV 
 Minimum HAM-D 
score of 20 and 
score of 2 on HAM-
D item 1 
 Depression 
symptoms for at 
least 1 mo 
Exclusion criteria: 






 Additional mental 
illnesses or organic 
mental disorder  
 Illicit drug and 
alcohol abuse 
 Clinically sig 
medical disease 
 ECT within last 2 
mos 
 Suicidal tendencies  
 
Mean age (yrs): 
D1: 40.6 
D2: 41.2  
Sex (% female): 
D1: 63.7 
D2: 59.4  





Mean HAM-D score 
at baseline: 
D1: 25.91 (0.46) 









ejaculation: 12.2% of 
men, 
impotence/erectile 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 













To compare sexual 
functioning associated 
with newer 
antidepressants using a 
validated scale in 
patients with MDD  
 





Overall study N: 
6000+ 
Intervention: 
D1: Bupropion IR , 
255mg/d (mean 
dose) 




































 sexually active at 
some point during 







Mean age (yrs): 
overall 30.2 
Sex (% female): 
overall: 77.2 
 













D4: 23 (only graph 
shown, data not 
reported) 
D5: 25 (only graph 
shown, data not 
reported) 
D6: 25 (only graph 
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Sexual Dysfunction (SD) 
Outcomes/ Adverse 
Events 
Method used to 
determine SD 
Author, Year 












To compare effects on 
sexual functioning and 
antidepressant efficacy of 
once-daily BUP XL and ESC 
in adults with MDD. 
Drugs, Doses, and Range 
D1: BUP XL (150-450 mg 1 
x daily): 150 mg 1x daily 
week 1 (low); 300 mg 1 
x daily during weeks 2 
to 4 (medium); on week 
5, daily dose could be 
increased to 450 mg 
(high) if additional 
efficacy was desired 
D2: ESC (10-20 mg 1 x 
daily): 10 mg 1 x daily 
during weeks 1 to 4 
(low); ESC dose could 
be increased to 20 mg 1 
x daily (medium) for 
weeks 5 to 8 if 










 Adults (age range): 
 18 years 
 Diagnosed with MDD 
according to DSM-III or 
-IV 
 HAM-D: HAM-D-17 
total score  19 at 
screening and on the 
day of randomization to 
treatment 
 Currently experiencing 
a MDE lasting  12 
weeks and < 2 years, 
but were otherwise 
healthy 
 Normal orgasm function 
as assessed by 
investigator interview 
and were willing to 
discuss their sexual 
functioning with 
investigator and 
engaged in sexual 
activity leading to 
orgasm at least once 
every 2 weeks. Patients 
who had a sexual 
desire disorder were 
eligible for study if 
investigoator 
considered it to be 
secondary to MDE. 
Groups similar at 
baseline 
Yes 
























Concomitant anergia, % 
NR 
Experienced prior 
D1:  Orgasm Dysfunction: 
15%; worsened sexual 
function: 20% 
D2:  Orgasm Dysfunction: 
30%; worsened sexual 
function: 36% 
D3:  Orgasm Dysfunction: 
9%; worsened sexual 
function: 15% 
Withdrawals due to 













Withdrawals due to lack 
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Sexual Dysfunction (SD) 
Outcomes/ Adverse 
Events 














 Additional mental 
illnesses or organic 
mental disorder not 
related to depression 
(e.g., schizophrenia, 
bipolar): A diagnosis of 
bipolar I or II disorder, 
schizophrenia, or other 
psychotic disorders 
 Suicidal tendencies 
(acute or other): history 
of attempted suicide 
within 6 months before 
screening. 
 Any sexual dysfunction 
at screening or at 
randomization except 
sexual desire disorder 




 History or current 
diagnosis of anorexia 
nervosa, bulimia, 
seizure disorder, or 
brain injury 




disorder, or acute 
stress disorder within 
12 months before study 
entry 
Outcome measures 
 HAM-D: HAM-D-17 
 CGI-S or CGI-I 
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Sexual Dysfunction (SD) 
Outcomes/ Adverse 
Events 
Method used to 
determine SD 
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Sexual Dysfunction (SD) 
Outcomes/ Adverse 
Events 
Method used to 
determine SD 
Author, Year 













Attrition rate, %:  
8 weeks: 
D1: 31.9 








Overall rate of 
attrition (8-
months) = 65.8. 
rate of attrition for 
acute treatment 
phase (initial 8 
weeks) = 28.5. 
 
Research objective 
Comparisons of changes in 
sexual functioning for DUL 
and ESC in which primary 
objective was to compare 
onset of antidepressant 
action for DUL 60 mg/day 
with that of ESC 10 mg/day. 
secondary objection was to 
compare differential drug 
effects on sexual functioning 
over acute and longer-term 
course of study. 
Drugs, Doses, and Range 
D1: DUL (40-60 mg 1-2 x 
daily): 60 mg/day 
(medium) for initial 
eight-week acute-
treatment phase; DUL 
60-120 mg/day 
(medium-high) during 
extension phase  
D2: ESC (10-20 mg 1 x 
daily): 10 mg/day (low) 
for initial 8-week acute-
treatment phase; 10-20 
mg/day (low-high) 











 Adults (age range): 
 18 years of age 
 Diagnosed with MDD 
according to DSM-III or 
-IV 
 MADRS: total score 
 22 
 CGI-S:  4 
Exclusion criteria: 
 Additional mental 
illnesses or organic 
mental disorder not 
related to depression 
(e.g., schizophrenia, 
bipolar): Illicit drug and 
alcohol abuse: history 
of substance 
dependence within past 
6 months 
 Clinically significant 
medical disease: 
Investigational drug use 
within last: A history of 
a lack of response, at 
any time, to an 
adequate trial of DUL 
( 60 mg/day for  4 
weeks), ESC ( 10 
mg/day for  4 weeks), 
or CIT ( 20 mg/day for 
 4 weeks) 
 ECT or transcranial 
magnetic stimulation 
within past year 
 Suicidal tendencies 
(acute or other): serious 
suicidal risk 
 Any current primary 
Groups similar at 
baseline 
Yes 




















Concomitant anergia, % 
NR 
Experienced prior 
depressive episodes, % 
NR 
Comments:  
The mean age of patients 
in DUL treatment group 
was significantly lower 
than that in ESC (41.1 
years vs. 43.3 years; P: 
0.036). CGI-S means 
D1: incidence of 
treatment-emergent 
sexual dysfunction (acute 
phase, 8 weeks): 17/51 
(33.3%); discontinuation 
due to SD Adverse 
Events, over 8 months: 
2/273 erectile dysfunction 
(0.7% of total population, 
2% of men) 
D2: incidence of 
treatment-emergent 
sexual dysfunction (acute 
phase, 8 weeks): 19/39 
(48.7%); discontinuation 
due to SD Adverse 
Events, over 8 months: 
7/274 (2.6%) 




At end point of acute-
treatment phase (8 weeks 
or last observation), 
categorical assessment of 
changes in global sexual 
functioning in DUL-treated 
male patients showed that 
54.4% reported 
improvement, 8.9% 
reported no change, and 
36.7% reported 
worsening; whereas in 
ESC-treated male 
patients, 34.2% reported 
improvement, 6.6% 
reported no change, and 
59.2% reported worsening 
(P = 0.019 DUL vs. ESC). 
CSFQ-14 
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Sexual Dysfunction (SD) 
Outcomes/ Adverse 
Events 
Method used to 
determine SD 
Duration 
8 months- included initial 8-
week, acute-treatment phase 
+ 24-week, double-blind, 
extension phase 
Type of depression 
MDD 
Intervention 
D1: DUL 60 mg QD 
D2: ESC 10 mg QD 
D3: PBO 
 
Axis I disorder other 
than MDD 
 Any anxiety disorder as 
a primary diagnosis 
within past 6 months 
 Treatment-resistant 
depression 
 Current and primary 
Axis II disorder that 
could interefere with 
compliance with study 
protocol 




 Treatment with MAOI 
within 14 days prior to 
visit 2; treatment with 
FLUOX within 30 days 




(SD) for treatment groups 
were reported at baseline. 
results are as follow: DUL 
60 mg QD: 4.2 (0.7); ESC 
10 mg QD: 4.2 (0.7); and 
PBO: 4.2 (0.7). 
 
Withdrawals due to 
adverse events, % 







Over 8-month course of 
study, withdrawal rates for 
sexual side effects did not 
differ for DUL (2/273) 
compared with ESC 
(7/274) (P = 0.07). Due to 
attrition and PBO rescue, 
number of PBO-treated 
patients significantly 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 












To compare sexual 
functioning as well as 
safety and efficacy of 
BUP SR and SER 




Overall study N: 
240 
Intervention: 
D1: SER: 50-200 mg/d 




 Adults 18+  
 Diagnosed with 
MDD according to 
DSM-III or -IV 
 Minimum HAM-D 
score of 18 




sexual activity at 














 Illicit drug and 
alcohol abuse 
 Suicidal tendencies  
 



















SD at 8 weeks:  
D1: Sexual Arousal 
Disorder: 9%; Orgasm 
Dysfunction: 36% 
D2: Sexual Arousal 
Disorder: 6%; Orgasm 
Dysfunction: 10%; 
total SD 16% 
D3: Sexual Arousal 
Disorder: 10%); 
Orgasm Dysfunction: 
5%); total SD 
(excluding sexual 
desire disorder): 15% 
 
structured clinical 
interview (only sexually 
active included); 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 











Comparison of BUP, 
FLUOX and PBO on 
safety, efficacy and 
sexual functioning in 
patients with recurrent 
major depression 




Overall study N: 
456 
Intervention: 
D1: FLUOX: 20-60 
mg/d (26) 




 Adults  
 Diagnosed with 
MDD according to 
DSM-III or -IV 
 Minimum HAM-D 
score of 20 
 Have sexual activity 
at least once every 
2 wks  
 Currently 
experiencing 
episode lasting 2 to 
24 mos 









 Illicit drug and 
alcohol abuse 
 Suicidal tendencies  






















[34/104 (33% of those 
at usual dose), 11 
(26% of those at high 
dose), 0 at low dose]; 
sexual arousal 
disorder (data only 
shown in graph), 
approx.): 12%; sexual 
desire disorder (data 
only shown in graph): 
24% 
D2: overall 15/135 
(11.1%) [15% (of 
those at usual dose), 
12% of those at high 
dose, 0 at low dose];  
sexual arousal 
disorder (data only 
shown in graph), 
approx.): (9/150) 6%; 
sexual desire disorder 




occurred sig more in 
FLUOX patients 
compared with PBO 
or BUP SR patients (P 
< 0.001) 
At endpoint, more 
FLUOX treated 
patients had sexual 
structured clinical 
interview (only sexually 
active included); 
diagnosis based on 
DSM-IV criteria (sexual 
function measured also 
at baseline; SD 
dichotomized as 
orgasm dysfunction, 
sexual desire disorder, 
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desire disorder than 
BUP SR treated 
patients  
(P < 0.05) 
Sig more buproion 
SR-treated patients 
were satisfied with 
sexual function 
(analysis only for 
patients satisfied at 
baseline; no data 
reported) P < 0.05 
Compliance: 96.8% to 














Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 











Comparison of efficacy 
and effects on sexual 
functioning of 
depressed patients 
using BUP, SER, or 
PBO 




Overall study N: 
239 
Intervention: 
D1: SER: 50-200 mg/d 
(mean = 121) 
D2: BUP: 150-400 
mg/d (mean = 293) 
Inclusion criteria: 
 Adults 18 and over 
 Diagnosed with 
MDD according to 
DSM-III or -IV 
 Minimum HAM-D 
score of 18 
 In stable 
relationship 
 Have normal sexual 
functioning and 
sexual activity at 
least once every 2 
wks 
 Current depressive 





















SD day 56: 
D1:  Sexual desire 
disorder: 28% (from 
baseline 43%); sexual 
arousal disorder: 6% 
(approx., data not 
reported, only shown 
in graph); orgasmic 
dysfunction (orgasm 
delay or failure); 41% 
(approx., data not 
reported, only shown 
in graph 
D2:  Sexual desire 
disorder: 19% (from 
baseline 39%); sexual 
arousal disorder: 6% 
(approx., data not 
reported, only shown 
in graph); orgasmic 
structured clinical 
interview, diagnosis 
according to DSM-IV 
definitions of SD; only 










Sexual Dysfunction associated with Second-Generation Antidepressants in Patients with Major Depressive Disorder - Results from a Systematic Review with Network Meta-Analysis. 
Drug Safety; U. Reichenpfader, G. Gartlehner, L.C. Morgan, A. Greenblatt, B. Nussbaumer, R. A. Hansen, M. Van Noord, L. Lux, and B. N. Gaynes. Corresponding author: 
 
U. 
Reichenpfader, Department for Evidence-based Medicine and Clinical Epidemiology, Krems, Austria; Department of Medical and Health Sciences - Division of Community Medicine, 









 Illicit drug and 
alcohol abuse 
 Suicidal tendencies  
 
dysfunction (orgasm 
delay or failure): 15% 
(approx., data not 
reported, only shown 
in graph) 
D3:  no data reported, 





both BUP and SER 
had higher sexual 
arousal disorder (P < 
0.05) than PBO 
Orgasmic dysfunction 
occurred sig more in 
SER patients 
compared with PBO 
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Sexual Dysfunction (SD) 
Outcomes/ Adverse 
Events 
Method used to 
determine SD 


























Comparison of the efficacy 
and safety of once-daily 
Venlafaxine extended 
release (XR) and immediate 
release versus placebo 
Drugs, Doses, and Range 
D1: Venlafaxine XR 75-150 
mg 
D2:  Venlafaxine IR 75-150 
mg 
D3: Placebo 
Fixed dose  
Flexible dose  
yes 
Dosages equivalent  
yes 




Type of depression 
 MDD 
Inclusion criteria: 
 Outpatients aged 18 
years or older  
 DSM-III-R criteria for a 
major depressive 
episode; 
 minimum baseline 
score of 20 on HAM-D 
21 
 not more than a 20% 
decrease in score 
between screening and 
baseline; and had 
symptoms of 
depression for at least 
one month 
Exclusion criteria: 
 lactating or of 
childbearing potential 
with a positive  
pregnancy test  
 history of clinically 
significant medical 
disease or clinically 
significant abnormalities 
 acute suicidal 
tendencies;  
 History of a seizure 
disorder; presence of 
an organic mental 
disorder; bipolar 
disorder; or a history of 
any psychotic disorder 
not associated with 
depression   
 Any investigational 
drug, antipsychotic 
drug, or ECT within 30 
days, fluoxetine within 
Groups similar at 
baseline - yes 


















Concomitant anergia, % 
NR 
Experienced prior 








D1: 27 (10/37)  
D2: 6 (2/31)   
D3: 0 (0/41)  
Withdrawals due to 
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Sexual Dysfunction (SD) 
Outcomes/ Adverse 
Events 
Method used to 
determine SD 
21 days, or monoamine 
oxidase 
inhibitor,,paroxetine, or 
sertraline within 14 
days, or use of any 
other antidepressant, 
anxiolytic, sedative-
hypnotic drug, or 
psychotropic drug or 
substance within 7 days 
 any nonpsychotropic 
drug with psychotropic 
effects  unless the 
dosage had been stable 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 











Comparison of efficacy 
and safety of FLUV and 
FLUOX 




Overall study N: 
184 
Intervention: 
D1: FLUOX: 20 mg/d 
D2: FLUV: 100 mg/d 
Inclusion criteria: 
 Adults 18 to 70  
 Diagnosed with 
MDD according to 
DSM-III or -IV 
 Minimum HAM-D 








 Additional mental 
illnesses or organic 
mental disorder  
 Illicit drug and 
alcohol abuse 
 Suicidal tendencies  
 
Mean age (yrs): 
D1: 42.0 
D2: 42.1  
Sex (% female): 
D1: 63.3 
D2: 62.7  












(5.7% of men) 
D2: ejaculatory 
dysfunction 1/33 (3% 
of men) 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
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analysis of 4 
studies - setting 






To assess sexual 
functioning in patients 
receiving DUL or PAR 
Duration of study: 
8 wk acute phase 
followed by a 26 wk 
extension phase (for 2 
of 4 studies) 
Study design: 
Pooled analysis of 4 
RCTs 
Overall study N: 
1,466 
Intervention: 
D1: DUL: 40, 80, or 120 
mg/d 
D2: PAR: 20 mg/d 
D3: PBO 
Inclusion criteria: 
 Diagnosed with 
MDD according to 
DSM-III or -IV 
Exclusion criteria: 
NR 
Mean age (yrs): 
NR 
Sex (% female): 
NR 






D1: acute phase (8 
weeks); in the patients 
not meeting ASEX 
criteria for SD 
(DULOX n=241): 
treatment-emergent 
SD 46.4%; AE (no 
sex-specific data for 
denominator shown): 
discontinuation due to 
erectile dysfunction 
1.2%; anorgasmia  
0.1%;  
D2: treatment-
emergent SD  61.4%, 
PAR (n=107); AE (no 
sex-specific data for 
denominator shown): 






emergent SD 28.8% 
ASEX (incidence of 
treat-emergent sexual 
dysfunction) sig higher 
for DUL vs. PBO 
DUL = 46.4% 
PBO = 28.8% 
t = 2.69, df = 1337,  
P = 0.007 
PAR vs. PBO 
PAR = 61.4% 
PBO = 28.8% 
P < 0.001 
DUL vs. PAR,  
P = 0.015 (incidence 
for DUL sig lower than 
incidence for PAR) 
ASEX (SD outcomes 
measured in 475 
patients who did not 
have sexual dysfunction 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 













To evaluate efficacy of 
DUL vs. PBO for 
treatment of MDD and 
associated painful 
symptoms 




Overall study N: 
245 
Intervention: 
D1: DUL 60 mg/d 
D2: PBO 
Inclusion criteria: 
 Adults 18 or older  
 MDD according to 
DSM-IV 
 Minimum HAM-D-17 
score of 15 




required for inclusion 
Exclusion criteria: 
 Additional mental 
illness or organic 
mental disorder  
 Psychotherapy 
within 6 wks 
 Substance abuse or 
dependence (within 
1 yr) 
 Clinically sig 
medical disease 
 Treatment resistant 
depression or lack 
of response of 
current MDD 
episode to 2 prior 
courses of therapy 
Mean age (yrs): 
D1: 42.44 
D2: 42.34 
Sex (% female): 
D1: 65.0 
D2: 68.0 




D1: 21.42 (4.11) 
D2: 21.14 (3.72) 
Baseline 100mm 
VAS (overall pain): 
D1: 29.02 (25.10) 






D1: 3/45 (6.7% of 
men) of DUL-treated 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 













and safety of DUL and 
PAR for treatment of 
MDD 




Overall study N: 
274 
Intervention: 
D1: DUL 80 mg/d 
D2: DUL 120 mg/d 
D3: PAR: 20 mg/d 
D4: PBO 
Inclusion criteria: 
 Adults 18 or older 
 Met DSM-IV and 
MINI criteria for 
MDD 
 CGI-S rating > 4  
 Diagnosed with 
MDD according to 
DSM-III or -IV 
 Minimum HAM-D 
score of 15 
Exclusion criteria: 
 Pregnant 
 Additional mental 
illnesses or organic 
mental disorder  
 Illicit drug and 
alcohol abuse 
 Clinically sig 
medical disease 
 Suicidal tendencies  
 




















Mean HAM-D score 
at baseline: 
D1: 19.9 (3.6) 
D2: 20.2 (3.4) 
D3: 20.3 (4.1) 
D4: 19.9 
treatment-emergent 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 













To compare long-term 
outcomes of duloxetine 




(TESD) and QoL in 
patients with MDD  
 





Overall study N: 
1647  
Intervention: 
D1: SSRI combined 
(SSRI monotherapy: 
median dose (min, 
max): paroxetine: 20.0 
(10.0, 480.0) mg/d, 
escitalopram: 10.0 (5.0, 
100.0) mg/d, sertraline: 
50.0 (20.0;400.0) mg/d,  
 fluoxetine: 20.0 (10.0, 
160.0) mg/d 
 
D2: Bupropion SR (300 
mg/d) 
Inclusion criteria: 
 Aged at least 18 
years 
 sexually active 
during 2 weeks prior 
to study entry 
without sexual 
dysfunction 
 Diagnosed with 
MDD according to 
DSM-IV or ICD-10 







 any antidepresant 
medication prior 1 
week to study 
(Fluoxetine: 1 
month) 
 any current 
psychiatric disorder 
other than MDD as 
defined in DSM-IV, 
current or past 
history of a manic or 
hypomanic episode, 
schizophrenia or 
any other psychotic 
disorder, mental 
retardation, organic 
mental disorders or 
mental disorders 
due to a general 
medical condition,  
Groups similar at 
baseline: 
partially not balanced 
Mean age (yrs): 
D1: 37.7 
D2: 38.2  
Sex (% female): 
D1: 58.3% 
D2: 51.8% 
Race (% white): 
D1: 18.1 
D2: 23.7  









TESD, 6 month 
D1: physician 
reported) 28.7% in 
SSRI group (n=509); 
patient-reported 
(TESD 6; ASEX)): 
approx. 36% (data 
only shown in graph 
 
D2: TESD 6 
(physician reported) 
23.4% 
{OR 0.77; duloxetine 
vs. SSRI 
monotherapy) of 
TESD 6 (95% CI: 
0.57; 1.04); P=0.087};  
patient-reported: 
approx. 16% (data 
only shown in graph) 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 















To compare efficacy 
and safety of SER with 
CIT in patients with 
major depression and 
examine occurrence 
and severity of sexual 
dysfunction symptoms 
beforea nd after 6 mos 
of treatment. 





for sexual dysfunction) 
Overall study N: 
400 
Intervention: 
D1: SER: 50-100 mg/d 
D2: CIT: 20-60 mg/d 
 
Inclusion criteria: 
 Adults 18 to 70  
 Diagnosed with 
MDD according to 
DSM-III or -IV 








 Additional mental 
illnesses or organic 
mental disorder  
 Illicit drug and 
alcohol abuse 
 Clinically sig 
medical disease 
 Suicidal tendencies  
 Previous treatment 
with SER or CIT w/o 
sig effect 
 
Mean age (yrs): 
D1: 47.0 
D2: 47.2  
Sex (% female): 
D1: 71 
D2: 72.5  








D1: AE, n : decreased 
sexual desire 7, 
erectile dysfunction 
(males): 2, ejaculatory 
dysfunction (males): 2 
, orgasm dysfunction: 
10; overall SD AE 
27/200 (13.5%)   
D2: decreased sexual 
desire (at baseline): 
46% of the women; 
47% of the men; at 
the end of the study 
(week 24): 20% of the 
women, 24% of the 
men; AE, n: 
decreased sexual 






overall SD AE 40/200 
(20%) 
No statistically sig 
diffs between SER 
and CIT in magnitude 
or frequency of 
adverse sexual side 
effects 
Female patients 




sexual desire and 
14.3% reported 
structured interview 
instrument (UKU Side 
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Method used to 
determine SD 
Analysis and Study 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 












Efficacy and tolerability 
of PAR and FLUOX 




Overall study N: 
128 
Intervention: 
D1: PAR: 20-50 mg/d 
(initial dosage of 
20 mg/d could be 
increased wkly by 
10 mg/d up to 50 
mg/d) 
D2: FLUOX: 20-80 
mg/d (initial 
dosage of 20 mg/d 
could be increased 
wkly by 20 mg/d up 
to 80 mg/d) 
D3: PBO 
Inclusion criteria: 
 Minimum HAM-D 
score of 18 
 Raskin Depression 
score of > 8 (and 
larger in value than 








 Additional mental 
illnesses or organic 
mental disorder  
 Illicit drug and 
alcohol abuse 
 ECT within last 3 
mos 
 Suicidal tendencies  












Mean HAM-D score 
at baseline: 
D1: 23.1 (3.4) 
D2: 23.9 (3.8) 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 


















and paroxetine in 
patients with MDD and 
to test whether the 
presence of insomnia 



















 Aged at least 18 
years 
 Diagnosed with 
MDD according to 
DSM-IV of at least 
4-weeks’ duration  
 Minimum baseline 
score of more than 
on the first 17 items 
(HAM-D-17) of the 
HAM-D-28.  
Exclusion criteria: 
 Pregnancy or 
breatfeeding 
 concomitant use of 
any antidepressant 
(other than study 
drugs), anxiolytic, 
other psychotropic 
medication within 7 
days before study 
entry, with the 
exception of chloral 
hydrate; use of 
MAOIs within 2 
weeks of active 
therapy or 
anticipated need to 
use an MAOI within 
5 weeks of 
discontinuing the 
study 
 serious suicidal risk; 
 serious comorbid 
illness that was not 
stabilized;  
 presence of a 
seizure disorder 
Groups similar at 
baseline: 
yes 
Mean age (yrs): 
D1: 42.1 
D2: 42.5  
D3: 44.0 
Sex (% female): 
D1: 63.0 
D2: 58.3 
D3: 57.3  
Race (% white): 
NR 
Mean (HAM-D-17) 







D2: 20% (abnormal 
ejaculation) 
D3: 0  





treat set at least one 
post-baseline 
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with a seizure 
occurring within the 
past year; 
 current or past 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 











To compare safety and 
efficacy of NEF with 
SER in outpatients with 
moderate to severe 
depression 




Overall study N: 
160 
Intervention: 
D1: NEF: 100-600 mg/d 
D2: SER: 50-200 mg/d 
Inclusion criteria: 
 Adults 18 or older  
 Diagnosed with 
MDD according to 
DSM-III or -IV 
 Minimum HAM-D 




 Illicit drug and 
alcohol abuse 
 Investigational drug 
use 
 Suicidal tendencies  
 
Mean age (yrs): 
D1: 43 
D2: 44.5  
Sex (% female): 
D1: 48 
D2: 55  
Race (% white): 
D1: 90 
D2: 79  
Baseline (HAM-A): 
NR 






D1: no sig AE on 
sexual function 
P < 0.01 




due to SD side 
effects: n=0; 
comparison of scores 
from item responces 
are shown an 
differences calculated; 
since data from 
unvalidated 
questionnaire only, no 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 












Efficacy and safety of 
BUP and FLUOX in 
depressed outpatients 




Overall study N: 
123 
Intervention: 
D1: BUP: 225-450 
mg/d (382) 
D2: FLUOX: 20-80 
mg/d (38) 
Inclusion criteria: 
 Adults 18 or older  
 Diagnosed with 
MDD according to 
DSM-III or -IV 
 Minimum HAM-D 








 Illicit drug and 
alcohol abuse 
 Clinically sig 
medical disease 
 Suicidal tendencies  
 
Mean age (yrs): 
D1: 40.9 
D2: 42.9  
Sex (% female): 
D1: 62 
D2: 61  












anorgasmia 1.7%, and 
libido decrease 1.7% 
(P = NR) 
standardized open 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 












To compare effects of 
NEF and SER on 
reemergence rates of 
sexual dysfunction in 
depressed patients 








Overall study N: 
75 
Intervention: 
D1: NEF: 200-400 mg/d 
D2: SER: 50-100 mg/d 
 
Inclusion criteria: 
 Adults 18 to 65 
 Diagnosed with 
MDD according to 
DSM-III or -IV 











 Additional mental 
illnesses or organic 
mental disorder 
 Illicit drug and 
alcohol abuse 
 Clinically sig 
medical disease 
 Investigational drug 
use within last 30 
days 
Mean age (yrs): 
D1: 43.2 
D2: 44.8 
Sex (% female): 
D1: 46 
D2: 48 











D1: 26% (10/39 
D2: 76% (25/33) 





treated (76% vs. 26%; 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 











Efficacy and safety of 
fluvoxamine and 
sertraline in the long-
term treatment of 
depression 















patients with prior 
episodes; depressive 
episode within past 
18 months; at least 4 




to DSM-IV; absence 
of other Axis I 
diagnosis 
Exclusion criteria: 
 Other Axis I 
diagnosis; low 
compliance with past 





recurrence cycle not 
longer than 18 
months 
 
Mean age (years): 
Drug 1: 47.3 
Drug 2: 49.0 
Sex (% female): 
Drug 1: 78 
Drug 2: 75 
Race (% white): 
Drug 1: NR 
















No, but not 
necessary since 
100% completed 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 











Comparison of NEF 
and PBO in prevention 
of depression 
recurrence 




Overall study N: 
165 for maintenance 
phase 
Intervention: 





 Adults 18 to 75 
 Diagnosed with 
MDD according to 
DSM-III or -IV 
 Minimum HAM-D 
score of 20 
Exclusion criteria: 
 Pregnant 
 Additional mental 
illnesses or organic 
mental disorder  
 Illicit drug and 
alcohol abuse 
 Clinically sig 
medical disease 
 ECT within last 3 
mos 
 Suicidial tendencies  
 















D1: 2/78 (2.6%) 
D2: 3/87 (3.4%) 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 







Eli Lilly and Co 
 
Research objective: 
To evaluate efficacy 
and safety of FLUOX 
compared to PBO in 
maintenance treatment 
of recurrent unipolar 
depression 
Duration of study: 
1 yr for maintenance  
(2 yrs total) 
Study design: 
RCT 









 Adults 18 to 65 
 Diagnosed with 
MDD according to 
DSM-III or -IV 
 Minimum HAM-D 
score of 18 
 At least one prior 
depressive episode 
in last 5 yrs  
 CGI-S score at least 




 Additional mental 
illnesses or organic 
mental disorder  
 Illicit drug and 
alcohol abuse 
 Suicidial tendencies  
 Previous resistance 
to pharmacologic 
treatment 
Mean age (yrs): 
D1: 44.4 
D2: 43.8 
Sex (% female): 
D1: 78.6 
D2: 78.6 





D1: 2.8 (2.0) 
D2: 3.1 (2.7) 
 
D1: 9/70 (12.9%) 
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Sexual Dysfunction (SD) 
Outcomes/ Adverse 
Events 
Method used to 
determine SD 
Author, Year 



































To determine antidepressant 
efficacy and tolerability of 
PAR CR and PAR IR in adult 
patients with MDD. 
Drugs, Doses, and Range 
 PAR (10-60 mg 1 x daily): 
20-50 mg/day (low to high) 
 PAR CR (12.5-75 mg 1 x 
daily): 25-62.5 mg/day 











Type of depression 
MDD 
Intervention 
D1: PAR CR 




 Adults (age range): 18-
65 
 Diagnosed with MDD 
according to DSM-III or 
-IV 
 HAM-D: 20 or more 
(and did not decrease 
by more than 25% 











agent (excluding chloral 
hydrate) 
 Additional mental 
illnesses or organic 
mental disorder not 
related to depression 
(e.g., schizophrenia, 
bipolar) 
 Illicit drug and alcohol 
abuse within 6 months 
of screening 
 ECT within last: 3 
months 
 Suicidal tendencies 
(acute or other) 
 History of brief 
depressive episodes 
(≤8 weeks) 
 Homicidal risk 
Groups similar at 
baseline 
Yes 




















Concomitant anergia, % 
NR 
Experienced prior 




Baseline mean HAM-A > 
25? 
NR  
Sexual dysfunction:  
Abnormal ejaculation: 
D1: overall SD AE: 24/212 
(11.3%) 
D2: at least 5% and 2x the 
rate of placebo-
group; 
D3: 1 female,1 male: total 
SD 2/211 (0.095%) 
 
non-leading question 
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Sexual Dysfunction (SD) 
Outcomes/ Adverse 
Events 
Method used to 
determine SD 




Dropout rate of 
patients with PAR 
IR sign. higher 
compared to PBO 
(P = 0.0008) 
 
 
 Currently taking PAR or 




 HAM-D: 17-item total 
score, depressed mood 
(item 1), psychic 
anxiety (item 10) 
Mean age at baseline 
Less than 65 years 
Mean HAM-D at baseline 
Greater than 17 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 
















and tolerability of MIR 
and VEN in treatment 
of hospitalized patients 
with DSM-IV diagnosis 
of severe depressive 
episode with 
melancholic features 




Overall study N: 
157 
Intervention: 
D1: MIR: 49.5 mg 
D2: VEN: 255.0 mg 
Inclusion criteria: 
 Adults 18 to 65 
 Diagnosed with 
MDD according to 
DSM-III or -IV 
 Minimum HAM-D 
score of 25 
 DSM-IV melancholic 
features  
Exclusion criteria: 






 Additional mental 
illnesses or organic 
mental disorder  
 Illicit drug and 
alcohol abuse 
 Clinically sig 
medical disease 
 Investigational drug 
use  
 ECT within last 3 
mos 
 Suicidal tendencies  
 Current episode  
> 12 mos  
 > 2 previous 
episodes of major 
depression that did 
not respond to AD 
therapy 
Mean age (yrs): 
D1: 45.9  
D2: 44.5  
Sex (% female): 
D1: 62.8 
D2: 68.4  




Mean HAM-D score 
at baseline: 
D1: 29.5 (3.0) 





sexual desire:  9/78 
(11.8%) ; (29/49, 
males/females);3 










2/25 (9.1% of men); 






UKU side effects 
symptoms scale (UKU 
symptoms with an 
incidence of 10% in 
either treatment group, 
or a statistically 
significant difference 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 











Compare NEF and 
PAR for treatment of 
depression and sleep in 
patients with mod-
severe MDD 




Overall study N: 
40 
Intervention: 
D1: NEF: 400-600 mg/d 
D2: PAR: 20-40 mg/d 
Inclusion criteria: 
 Adults 18 or older 
 Diagnosed with 
MDD according to 
DSM-III or -IV 
 Minimum HAM-D 








 Additional mental 
illnesses or organic 
mental disorder  
 Illicit drug and 
alcohol abuse 
 Investigational drug 
use within last 30 
days 
 Shift workers 
 Current sleep 
disorders 
Mean age (yrs): 
D1: 42.75 
D2: 42.95  
Sex (% female): 
D1: 60 
D2: 55  




Mean HAM-D score 
at baseline: 
D1: 22 
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Method used to 
determine SD 
Analysis and Study 














prophylactic efficacy of 
CIT vs. PBO in 
unipolar, recurrent 
depression following 
response to treatment 
with CIT in previous 
study periods 




Overall study N: 
(For period III): 269 
Intervention: 
D1: CIT: 20, 40, or 60 





 Adults 18 to 65 
 Diagnosed with 
MDD according to 
DSM-III or -IV 
 MADRS ≥ 22 
 Two or more 
previous depressive 
episodes (one 







 Additional mental 
illnesses or organic 
mental disorder  
 Illicit drug and 
alcohol abuse 
 Clinically sig 
medical disease 
 ECT within last 3 
days to 8 wks  
 Suicidial tendencies 
 MADRS item 10 ≥ 5 
 Current depressive 
episode longer than 
6 mos 
 Family history of 
bipolar disorder 
Mean age (yrs): 
D1: 43.8 (9.7) 
D2: 42.4 (11.5) 
Sex (% female): 
D1: 67.4 
D2: 75 
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Method used to 
determine SD 
Analysis and Study 


















To test efficacy and  
safety of a well-
characterized 
Hypericum perforatum 
extract (LI-160) against 
placebo and sertraline 
in patients with MDD  
 








D2: SER: 50-100mg/d 
Inclusion criteria: 
 Aged at least 18 
years 
 Diagnosed with 
MDD according to 
DSM-IV  
 Minimum HAM-D  
total score of at 
least 20 at 
screening and 
baseline visits 
 Minimum Global 
Assessment of 
Functioning (GAF) 
total score of at 
least 20 
Exclusion criteria: 
 score above 2 on 
the HAM-D suicide 
item, attempted 
suicied in teh last 
year; 
 pregnancy or 
planning pregnancy 
or breastfeeding; 
 liver disease or 
unstable serious 
disease 
 daily use of 
sertraline or 
Hypericum in the 







 any current 
Groups similar at 
baseline: 
yes 
Mean age (yrs): 
D1: 40.1 
D2: 43.9  
Sex (% female): 
D1: 66.4 
D2: 66.7 














D2:  32% 
spontaneously reported 
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other than MDD as 
defined in DSM-IV, 
 current or past 
history of a manic or 
hypomanic episode, 
schizophrenia or 
any other psychotic 
disorder, mental 
retardation, organic 
mental disorders or 
mental disorders 
due to a general 
medical condition, 
any 
 substance abuse 
disorder within the 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 





















To compare efficacy, 
safety and tolerability of 
Lu AA21004 at 5 
mg/day compared with 
placebo over 8 weeks 
in elderly patients with 
MDD with duloxetine 
(60mg/day) 
as an active reference 








D2: DUL: 60mg/d 
Inclusion criteria: 
 Aged at least 65 
years 
 Diagnosed with 
MDD according to 
DSM-IV of at least 
4-weeks’ duration 
and with at least 
one previous MDE 
before the age of 60 
years 
 Minimum MADRS  
total score of at 








 Mini-Mental State 
Examination 
(MMSE) score of 
less than 24 at 
screening 
 any current 
psychiatric disorder 
other than MDD as 
defined in DSM-IV, 
 current or past 
history of a manic or 
hypomanic episode, 
schizophrenia or 
any other psychotic 
disorder, mental 
retardation, organic 
mental disorders or 
mental disorders 
Groups similar at 
baseline: 
yes 
Mean age (yrs): 
D1: 39 
D2: 40  
Sex (% female): 
D1: 70.3 
D2: 70.9  
Race (% white): 
D1: 95.9 
D2: 95.4  
Baseline (HAMD-24): 
D1: 29.4 
D2: 28.5  







D2: 6 patients (male) 
6/51 (11.8% of men): 
[abnormal orgasm and 
erectile dysfunction 






non-leading question to 
ascertain AE; no 
targeted questions/ no 
specific instrument  






treat set – the full-
analysis set (FAS), 
comprising all 
patients in the APTS 
who had at least one 
valid postbaseline 
assessment of the 
primary efficacy 
variable (HAM-D24 
total score)  
Risk of Bias: 
low 
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due to a general 
medical condition, 
any 
 substance abuse 
disorder within the 
previous 6 months,  
 presence or history 
of a clinically 
significant 
neurological 
 Suicidal tendencies 
 elevated intraocular 
pressure or at risk 






disease, a clinically 
significant unstable 
illness 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 













To determine if 
maintenance therapy 
with SER can 
effectively prevent 
recurrence of 
depression in patients 
with chronic major 
depression or double 
depression 




Overall study N: 
161 
Intervention: 
D1: SER: 50-200 mg/d  
D2: PBO  
Inclusion criteria: 
 Diagnosed with 
MDD according to 
DSM-III or -IV 
 Minimum HAM-D 
score of 18 
 MDD with or without 
dysthymic disorder 
 Chronic depression 
defined as 
depression of at 
least 2 yrs duration 
 3 phase study 
Exclusion criteria: 
NR 
Mean age (yrs): 
D1: 40.8 
D2: 42.4 
Sex (% female): 
D1: 62 
D2: 69 





D1: 5.5 (4.2) 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 













To compare FLUV and 
PAR in treatment of 
outpatients with major 
depression 




Overall study N: 
60 
Intervention: 
D1: FLUV: 50-150 mg/d 
D2: PAR: 20-50 mg/d 
Inclusion criteria: 
 Adults 18 to 65 
 MDD diagnosis 
according to DSM-
III or -IV 
 Minimum HAM-D 
score of 20; 
minimum score of 2 
on “depressed 








 Additional mental 
illnesses or organic 
mental disorder  
 Illicit drug and 
alcohol abuse 
 Clinically sig 
medical disease 
 Suicidal tendencies  
 Used a drug within 
30 days with 
anticipated major 
organ toxicity 





Mean age (yrs): 
D1: 42.7 
D2: 39.9  
Sex (% female): 
D1: 53 
D2: 53  
Race (% white): 
D1: 87 
D2: 93  
Baseline (HAM-A): 
NR 








(7.1% of men); 
decreased libido: 




(21.4% of men); 
decreased libido: 5/30 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 








H. Lundbeck A/S 
 
Research objective: 
Efficacy and tolerability 
of ESC compared to 
CIT and PBO in 
depression in primary 
care setting 




Overall study N: 
315 
Intervention: 
D1: CIT: 20-40 mg/d 
(mean 28.4) 




 Adults 18 to 65  
 Diagnosed with 
MDD according to 
DSM-III or -IV 








 Additional mental 
illnesses or organic 
mental disorder  
 Illicit drug and 
alcohol abuse 
 Suicidal tendencies  
 












Mean HAM-D score 
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Sexual Dysfunction (SD) 
Outcomes/ Adverse 
Events 
Method used to 
determine SD 
Author: 












to-treat set at 
least one post-




were taken and 
at least one dose 
of medication 
 
Overall rate of 





Research objective  
To determine 
antidepressant efficacy and 
tolerability of Bupropion in 
lower daily dosages 




Doses, and Range 









Type of depression 
MDD 
Inclusion criteria 
 Adults (age range):  18 
years 
 DSM-III-R for current 
major depression 
 Be depressed for 4 
weeks to 2 years 
 HAM-D total score at 
baseline at least 20 
Exclusion criteria 
 Pregnancy or 
breatfeeding 
 concomitant use of any 
antidepressant (other 
than study drugs), 
anxiolytic, other 
psychotropic medication 
within 7 days before 
study entry; use of 
MAOIs within 2 weeks 
before study entry 
 previous treatment with 
bupropion  
 serious suicidal risk; 
 history of anorexia or 
bulimia 
 serious comorbid illness  
 preposition to seizures  
 substance abuse 
disorder withen the past 
12 months to study entry 
Groups similar at 
baseline 
Yes 
n =  
D1: 67 
D2: 75 
Mean age, years (SD) 
D1: 41.9  
D2: 40.8 
Sex, % female  
D1: 64.6 
D2: 65.1 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 













To compare safety and 
side-effect profiles of 
NEFA, FLUOX, SER, 
VENLA and PAR in a 
cohort study 
Duration of study: 
N/A 
Study design: 
Cross sectional – 
prescription event 
monitoring 
Overall study N: 
63,913 
Intervention: 
D1: NEFA (n=11,834) 
D2: FLUOX (n=12,962) 
D3: SER (n=12,734) 
D4: PAR (n=13,741) 
D5: VENLA (n=12,642) 
 
Inclusion criteria: 






54.6% to 64.1%  




D4: 49  
D5: 48 
 




D4: 67.5  
D5: 65.0 
 






incidence density rate: 
number of AE/1000 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 











Efficacy and safety of 
SER and VEN in 
outpatients with major 
depression 




Overall study N: 
147 
Intervention: 
D1: VEN: 75-150 mg/d 
D2: SER: 50-100 mg/d  
  
Inclusion criteria: 
 Adults 18 to 65  
 Minimum HAM-D 




 Additional mental 
illnesses or organic 
mental disorder  
 Illicit drug and 
alcohol abuse 
 Clinically sig 
medical disease 
 
Mean age (yrs): 
D1: 44.1 
D2: 41.0  
Sex (% female): 
D1: 65 
D2: 67  




Mean HAM-D score 
at baseline: 
D1: 25.5 (3.5) 











D1: 6/75 (8%) 
D2: 4/72 (5.6%) 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 

















To evaluate safety 
profile of SER vs. other 
SSRIs directly following 
introduction of SER to 
Dutch market 
Duration of study: 


















FLUV, or PAR used 
as controls 
Exclusion criteria: 




Mean age (yrs): 
41 (median) 
Sex (% female): 
64.1% 












D1: AE sexual 
dysfunction: N 
(incidence: number of 
first adverse 
events/1000 person-
years): loss of libido 
31 (0.27); ejaculation 
failure 14 (0.12), 
Impotence (male) 9 
(0.08; other sexual 
function disorder 
(male) 4 (0.03); 
anorgasmia (female) 6 
(0.05); other sexual 
function disorder 
(female) 3 (0.03); N 
(%) of sexual 
dysfunction AE %: 
male ejaculation: 




(3.7% of men); loss of 
libido 31/659 (4.7% of 
all); female 
anorgasmia 6/415 
(1.4% of women); 
other sexual function 
disorder (female) 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 















Duration of study: 
Carried out between 


















 Normal sexual 
functioning prior to 
taking 
antidepressants 
 Treatment with 
antidepressant 
alone or combine 
with benzodiazepine 
 Previous regular 
and satisfactory 
sexual practices 
 Occurrence of 
sexual dysfunction 




 Prior sexual 
dysfunction 




 Treatment with 
hormones or any 
other drug capable 
of interfering with 
sexual intercourse 
 Sig intercurrent 
diseases affecting 
sexual function 
 Substance abuse 
Mean age (yrs): 
Overall: 39.8 
Sex (% female): 
Overall: 60 







Overall incidence of 
sexual dysfunction 
was 59.1%  









NEF, 8%  
Men had a higher 
frequency of sexual 
dysfunction (62.4%) 
than women (56.9%), 

















Sexual Dysfunction associated with Second-Generation Antidepressants in Patients with Major Depressive Disorder - Results from a Systematic Review with Network Meta-Analysis. 
Drug Safety; U. Reichenpfader, G. Gartlehner, L.C. Morgan, A. Greenblatt, B. Nussbaumer, R. A. Hansen, M. Van Noord, L. Lux, and B. N. Gaynes. Corresponding author: 
 
U. 
Reichenpfader, Department for Evidence-based Medicine and Clinical Epidemiology, Krems, Austria; Department of Medical and Health Sciences - Division of Community Medicine, 














Method used to 
determine SD 
Analysis and Study 










H. Lundbeck A/S 
 
Research objective: 
To compare efficacy 
and tolerability of ESC 
to VEN XR in primary 
care patients with MDD 




Overall study N: 
297 
Intervention: 
D1: ESC: 10-20 mg/d 
(12.1) 
D2: VEN: 75-150 mg/d 
(95.2) 
Inclusion criteria: 
 Adults 18 to 85 
 Diagnosed with 
MDD according to 
DSM-III or -IV 








 Additional mental 
illnesses or organic 
mental disorder  
 Illicit drug and 
alcohol abuse 
 Clinically sig 
medical disease 
 Suicidal tendencies  
Mean age (yrs): 
D1: 49 
D2: 47  
Sex (% female): 
D1: 73 
D2: 71  











dysfunction (data only 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 








H. Lundbeck A/S 
 
Research objective: 
Efficacy of ESC vs. CIT 
in outpatients 




Overall study N: 
294 (ITT = 280) 
Intervention: 
D1: ESC: 20 mg/d 
D2: CIT: 40 mg/d 
Inclusion criteria: 
 Adults 18 to 65 
 Diagnosed with 
MDD according to 
DSM-III or -IV 







 Additional mental 
illnesses or organic 
mental disorder  
 Illicit drug and 
alcohol abuse 
 
Mean age (yrs): 
D1: 44.1 
D2: 46.2  
Sex (% female): 
D1: 81.7 
D2: 72  




Mean HAM-D score 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 











Comparison of efficacy 
and safety of FLUV and 
SER in treatment of 
depression 




Overall study N: 
95 
Intervention: 
D1: SER: 50-200 mg/d 
(137.1) 




 Adults 18 to 65 
 Diagnosed with 
MDD according to 
DSM-III or -IV 
 Minimum HAM-D 
score of 20 
 HAM-D depressed 
mood item of at 
least 2  
 Covi anxiety score 
less than Raskin 
score 










 Additional mental 
illnesses or organic 
mental disorder  
 Patients itolerant of 
SSRI side effects 
 
Mean age (yrs): 
D1: 41.2 
D2: 38.5  
Sex (% female): 
D1: 60.9 
D2: 61.2  
Race (% white): 
D1: 84.8 
D2: 98.0  
Baseline (HAM-A): 
NR 
Mean HAM-D score 
at baseline: 
D1: 23.15 (2.77) 
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Sexual Dysfunction (SD) 
Outcomes/ Adverse 
Events 
Method used to 
determine SD 
Author, Year 
Nierenberg et al, 


























To compare speed of onset 
of antidepressant efficacy for 
DUL and ESC. 
Drugs, Doses, and Range 
D1: DUL (40-60 mg 1-2 x 
daily): 60 mg QD; 
medium 
D2: ESC (10-20 mg 1 x 














Type of depression 
MDD 
Intervention 
D1: DUL 60 mg QD 




 Adults (age range): 18-
79 
 Diagnosed with MDD 
according to DSM-III or 
-IV 
 MADRS:  22 
 CGIS:  4 
Exclusion criteria: 






 Additional mental 
illnesses or organic 
mental disorder not 
related to depression 
(e.g., schizophrenia, 
bipolar): bipolar, schizo, 
Axis II disorder 
 Illicit drug and alcohol 
abuse: within last 6 
mos. 
 Clinically significant 
medical disease 
 ECT within last: year 
 Suicidal tendencies 
(acute or other): 
decided by investigator 
 Other: anxiety within 
last 6 mos. 
Outcome measures 
 HAM-D: 20% decrease 
from baseline 
 CGI-S or CGI-I: 17% 
decrease from baseline 
Groups similar at 
baseline 
Yes 




















Concomitant anergia, % 
NR 
Experienced prior 
depressive episodes, % 
NR 
 
D1: AE: anorgasmia 
4.4%; decreased libido 
14/273 (5.1%) 
D2: erectile dysfunction 
2/274  (0.7%); 
anorgasmia 10/274 
(3.6%); decreased libido 
11/274 (4%); overall SD: 
23/274 (8.4%) 
D3: anorgasmia 0; 
decreased libido 3/137 
(2.2%); overall: 2.2% 






Withdrawals due to 
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Sexual Dysfunction (SD) 
Outcomes/ Adverse 
Events 
Method used to 
determine SD 











Sexual Dysfunction (SD) 
Outcomes/ Adverse 
Events 
Method used to determine 
SD 
Author, Year 































To assess for efficacy and 
sefety of DUL doses of 80 
and 120 mg/day in treatment 
of MDD. 
Drugs, Doses, and Range 
D1: DUL: 40 mg 2 x daily  
D2: DUL: 60 mg 2 x daily  


















 Adults (age range): at 
least 18 years  
 Diagnosed with MDD 
according to DSM-III or 
-IV 
 HAM-D: HAM-D total 
score greater than or 
equal to 15 
 CGIS: greater than or 
equal to 4 
Exclusion criteria: 
 Additional mental 
illnesses or organic 
mental disorder not 
related to depression 
(e.g., schizophrenia, 
bipolar) 
 Illicit drug and alcohol 
abuse 






neurological disease, or 
clinically significant 
laboratory abnormality 
 Investigational drug use 
within last 
 Suicidal tendencies 
Groups similar at 
baseline 
Yes 





Mean age, years 
D1: 44.7 (10.1) 
D2: 46.5 (12.7) 
D3: 44.0 (10.8) 
D4: 45.8 (10.6) 





Race, % white 
100 
Baseline HAM-A 
D1: 18.8 (4.4) 
D2: 19.3 (4.9) 
D3: 19.5 (5.7) 
D4: 19.9 (5.1) 
Insomnia, % 
NR 




after 8 weeks (no 







Authors also utilized 
IRSD-F. Reports given 
were to validate Sex FX 
scale by examining 
correlations between Sex 
FX total and overall 
satisfaction scores and 
IRSD-F total score. A 
statistically significant 
negative correlation was 
found for both men and 
women between IRSD-F 
total and Sex FX scores 
reflecting inverse relation 
between function on Sex 
FX and dysfunction on 
IRSD-F. 
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Sexual Dysfunction (SD) 
Outcomes/ Adverse 
Events 





(acute or other) 
 Lack of response to at 
least two adequate 
courses of 
antidepressant therapy 
(at least 4 weeks' 
duration) within 
therapeutic dose range 
during their current 
MDD episode. 
Outcome measures 
 HAM-D: mean change 
from baseline in HAM-D 
17 total score after 8 
weeks of treatment 
 MADRS 
 CGI-S 
 PGI scale 
 SDS 
 VAS) for pain 
 SSI 
Experienced prior 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 













of Mental Health 
 
Research objective: 
To determine whether 
testosterone and 
FLUOX is superior to 
PBO for depression, 
fatigue, or both 




Overall study N: 
123 
Intervention: 
D1: FLUOX: 20-60 
mg/d 
D2: PBO Testosterone 
200-400 mg biwkly 
 
Inclusion criteria: 
 Adults 18 or older 
 Diagnosed with 
MDD according to 
DSM-III or -IV 
 HIV seropositive 
 Dysthymia 
 Male 
 Negative PSA  




 Additional mental 
illnesses or organic 
mental disorder  
 Illicit drug and 
alcohol abuse 
 Investigational drug 
use within last 5 
wks 
 ECT  
 Suicidal tendencies  
 Psychotherapy 
started in last mo 
 Use of anabolic 
steroids 
 Current/anticipated 
change in ARV 




partners of unknown 
or negative HIV 
status 
Mean age (yrs): 
D1: 40 
D2: 41 
Sex (% female): 
D1: 0 
D2: 0 






D1: 18.2 (4.5) 
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Method used to 
determine SD 
Analysis and Study 











To compare efficacy, 
















 Adults 18 to 65 
 Diagnosed with 
MDD according to 
DSM-III  
 Minimum HAM-D 
score of 18 on the 
first 18 items of the 
HAM-D 
 less than a 25% 
decrease in HAM_D 
score compared 
with screening 
value; higher score 
on the Raskin 
Depression Scale 
than on Covi 
Anxiety Scale 
Exclusion criteria: 






 Illicit drug and 
alcohol abuse 
 significant medical 
conditions 
 Suicidal tendencies  
 Schizophrenia or 
schizoaffective 
disorder 








Sex (% female): 
D1: 53 
D2: 52 







disorder 15/70 (21.4% 
of men) 
D2:  ejaculation 
disorder 1/72 (1.4% of 
men) 




modified ITT (at 
least one efficacy 
assessment 
available and at lest 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 
























To analyze the 
objective and 
subjective effects of 
nefazodone and 
fluoxetine on sleep as 
well as the timing of 
these effects over an 8-
week, acute-phase 
treatment period in 
patients with MDD. 




Overall study N: 
125 
Intervention: 
D1: Nefazodone, up to 
200-500mg/d  
D2: Fluoxetine up to 
40mg/d 
Inclusion criteria: 
 Adults 19 to 55 
 Diagnosed with 
MDD according to 
DSM-III-R 
 Minimum score of 
18 on the first 17 





 engaged in 














disorder within the 





 any other major 
lifetime DSM-III-R 




Mean age (yrs): 
D1: 46.0 
D2: 37.0 
Sex (% female): 
D1: 59 
D2: 70 





D1: 22.9  











modified ITT (all 
patients randomized 
to treatment, 
received a dose of 
study drug, and had 
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eating, panic, or 
obsessive– 
compulsive 
 pregnant, lactating, 
or sexually active 
women not using an 
adequate method of 
contraception. 
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Sexual Dysfunction (SD) 
Outcomes/ Adverse 
Events 


















list name): Wyeth 
Research 
Overall rate of 
attrition, %  
30% 





due to adverse 




Attrition due to 




Research objective  
To compare efficacy of 
VEN IR and FLUOX with 
PBO in a sample of 
patients over age of 65 with 
depression. 
Intervention Drugs, 
Doses, and Range 
D1: VEN 37.5-225 mg/day 
(low - high) 









Type of depression 
Major depressive disorder 
unipolar depression (single 
or recurrent, nonpsychotic)  
Inclusion criteria 
 Adults (age range): 65 
years and older 
 HAM-D: 21-item HAM-D 
score  20 at initial visit 
 Not living in a residential 
setting 
 Unipolar (single or 
recurrent, nonpsychotic), 
with a current episode of 






medications: within prior 
30 days 
 Additional mental 
illnesses or organic 
mental disorder not 
related to depression 
(e.g., schizophrenia, 
bipolar) 
 Illicit drug and alcohol 
abuse within past year 
 Clinically significant 
medical disease 
 Investigational drug use 
within last: 30 days 
 ECT within last: 3 
months 
 Suicidal tendencies 
(acute or other) 
 MMSE score = < 18 
 FLUOX or VEN in past 
six months 
 Astemizole, cisapride, 
Groups similar at 
baseline 
Yes 


















Insomnia, %:  
NR 
Concomitant anergia, %  
NR 
Experienced prior 
depressive episodes, %  
NR 
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Sexual Dysfunction (SD) 
Outcomes/ Adverse 
Events 
Method used to 
determine SD 





Risk of Bias 
Fair 
sumatriptan, terfenadine, 
PAR, SER, or any 
monoamine oxidase 
inhibitor within 14 days 
 Used any other 
antidepressant, 
anxiolytic, or sedative-
hypnotic durg (except 
choloral hydrate) 
 Known hypersensitivity 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 











To compare efficacy 
and safety of BUP SR 









Overall study N: 
248 
Intervention: 
D1: BUP: 100-300 
mg/d (mean 238 
mg/d) 
D2: SER: 50-200 mg/d 
(mean 114 mg/d) 
Inclusion criteria: 
 Adults 18 to 76 
 Diagnosed with 
MDD according to 
DSM-III or -IV 
 Minimum HAM-D 
score of 18 
 Stable relationship 









 Additional mental 
illnesses or organic 
mental disorder  
 Suicidal tendencies  
 History/current 





Mean age (yrs): 
D1: 39 
D2: 40  
Sex (% female): 
D1: 48 
D2: 48  
Race (% white): 
D1: 93 
D2: 94  
Baseline (HAM-A): 
D1: 16.6 (5.2) 
D2: 16.6 (5.2) 
Mean HAM-D score 
at baseline: 
D1: 24.8 (4.6) 
D2: 24.8 (4.6) 
 
D1: overall % of 
sexual desire disorder 
(baseline): 54%, at the 
end of the treatment 







15%; women: 7%; 
D2: overall % of 
sexual desire disorder 
(treatment-emergent) 






52%, or premature 
ejaculation): men 




for SD, not specified; 
patient satisfaction with 
overall sexual 
functioning using a 6-
point, Likert-scale; 
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Sexual Dysfunction (SD) 
Outcomes/ Adverse 
Events 






Eight U.S. sites 

























To compare efficacy, safety, 
and tolerability of SER and 
VEN XR in outpatients with 
MDD. 
Drugs, Doses, and Range 
D1: SER (25-200 mg 1 x 
daily): 50-150mg QD; 
Low-Medium; Maximum 
dose as tolerated. 
D2: VEN XR (75-225 mg 1 x 
daily): 75-225 mg QD; 
Low-High; Maximum 




















 Adults aged 18+ 
 Diagnosed with MDD 
according to DSM-III or 
-IV: 
 Single episode or 
recurrent w/o psychotic 
features. 
 HAM-D: ≥ 18 on HAM-
D17 and ≥ 2 on item 1 
(depressed mood). 
Exclusion criteria: 
 Pregnant: Positive 
pregnancy test 
excluded participant. 




 Use of an 
antidepressant within 2 
weeks of baseline 
(4 weeks for FLUOX) 
 Use of any 
psychotropics within 1 
week of baseline 
(except zolpidem or 
zopiclone) 
 Use of benzodiazepines 
taken on a regular, daily 
basis within 4 weeks of 
baseline 
 Monoamine oxidase 
inhibitors within 14 days 
of baseline evaluation. 
 Additional mental 
illnesses or organic 
mental disorder not 
Groups similar at 
baseline 
Yes 
n =  
D1: 82 
D2: 78 
Mean age, years (SD) 
D1: 41.2 (12.0) 
D2: 37.2 (11.6) 
Sex, % female 
D1: 46 
D2: 61 
Race, % white 
D1: 83 
D2: 84 
Baseline HAM-A (SD) 
D1: 15.7 (5.1) 
D2: 16.0 (4.4) 
Insomnia, % 
NR 
Concomitant anergia, % 
NR 
Experienced prior 






Sexual dysfunction:  
D1: 15/82 (18.3%) 
D2: 16/78 (20.5%) 
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Sexual Dysfunction (SD) 
Outcomes/ Adverse 
Events 
Method used to 
determine SD 
related to depression 
(e.g., schizophrenia, 
bipolar) 
 Current or past 
diagnosis of bipolar 
disorder or any 
psychotic disorder 
 Current diagnosis of 
delirium or dementia 
 A mental condition 
rendering patient 
unable to understand 
study 
 Schizoid, schizotypal, 
or borderline 
personality disorder. 
 Illicit drug and alcohol 
abuse 
 Alcohol or 
Ddependence or abuse 
within last 6 months. 
 Clinically significant 
medical disease 
 Any serious and/or 
unstable medical 
condition 
 Abnormal baseline 
laboratory finding 
considered indicative of 
conditions that might 
affect study results 
 Impaired hepatic 
function 
 Impaired renal function 
 History of seizure 
disorder. 
 Investigational drug use 
within last: 90 days 
 ECT within last: 30 
days 
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Sexual Dysfunction (SD) 
Outcomes/ Adverse 
Events 
Method used to 
determine SD 
 Suicidal tendencies 
(acute or other): Score 
of 3 or 4 on suicide item 
of HAMD. 
 Previous non-response 
to SER, VEN XR, or to 
2 antidepressants in 
current episode 
 Use of herbal and/or 
homeopathic remedies 
within 2 weeks of 
baseline 
 History of intolerance or 
hypersensitivity to SER 
and/or VEN XR 
 Likelihood of requiring 
treatment during study 
period with drugs not 




 CGI-S and CGI-I 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 










To evaluate efficacy of 
VEN XR in prevention 
of relapse of 
depression by 
continuation treatment 
Duration of study: 




Overall study N: 
318 entered relapse 
prevention study (490 
in acute phase) 
Intervention: 





 Adults 18+  
 Diagnosed with 
MDD according to 
DSM-III or -IV 
 Minimum HAM-D 
score of >20  
 No greater than 
20% decrease in 









 Clinically sig 
medical disease 
 Investigational drug 
use  




 FLUOX within 30 
days 
Mean age (yrs): 
D1: 43 
D2: 41 
Sex (% female): 
D1: 102 (66%) 
D2: 86 (62%) 










ejaculation 5.3% of 
men 
D2: abnormal 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 











To evaluate efficacy 
and tolerability of VEN 
XR once daily in 
outpatients with MDD 












 Adults 18 and older  
 Diagnosed with 
MDD according to 
DSM-IV with 
duration of at least a 
month 
 Minimum HAM-D 
score of 20 on the 
HAM-D-21 and less 
than a 20% 





 Pregnant or 
breastfeeding 
 antipsychotic 
medications or ECT 
within 30 days prior 
to study entry 
 fluoxetine within 21 
days prior to study 
entry or MAOs 
within 14 days prior 
to study entry 
 Illicit drug and 
alcohol abuse 
 significant medical 
conditions 
 acute suicidal 
tendencies 
 history of seizures 
 history oof bipolar or 
psychotic disorder 
Mean age (yrs): 
D1: 40 
D2: 42 
Sex (% female): 
D1: 60 
D2: 61 
Race (% white): 
NR 
Mean HAM-D-21 
score at baseline: 
D1: 25 
D2: 24 






D1:  abnormal 
ejaculation/orgasm: 
men: 8/35 (22.9% of 
men); women: 2/60 
(3.3% of women);  
impotence 5/35; 
female anorgasmia 
4/60; SD AE: overall: 
19/95 (20%) 










modified ITT (at 
least received one 
dose of study 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 












To evaluate efficacy 
and tolerability of lower 
doses of paroxetine CR 
in patients with MDD  
 








D2: Paroxetine CR 
12.5mg/d 
D3:  Paroxetine CR 
25mg/d 
Inclusion criteria: 
 Adults 18 and older  
 Diagnosed with 
MDD according to 
DSM-IV with 
duration of at least a 
month 
 Minimum HAM-D 
score of 20 on the 
HAM-D-17 and a 
score of more than 
2 on item 2 on 




 any current 
psychiatric disorder 





 lifetime history of a 




disorder or bipolar 
disorder 
 general medical 
condition, any 
 substance abuse 
disorder within the 
previous 3 months,  
 substance 
dependence within 
the previous 6 
months 
Groups similar at 
baseline: 
yes 
Mean age (yrs): 
D1: 38.4 
D2: 38.6  
D3: 39.4 
Sex (% female): 
D1: 61.6 
D2: 54.2  
D3: 59.5 
Race (% white): 
D1: 74.0 
D2: 76.5  
D3: 76.4 
Mean (HAMD-27) 











D1: men & women, 
decrease2 libido: 
6/146 (4.2%) 




4/70 (5.7% of men); 




6/70 (8.6% of men) 
 
patients questioned at 






treat set comprising 
all patients who had 
at least one valid 
postbaseline 
assessment of the 
primary efficacy 
variable and 
received at least one 
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 presence or history 
of a clinically 
significant 
neurological 
 Suicidal tendencies 
 lifetime history of 
seizures 
 ECT within pevious 
3 months 
 use of study 
medication within 
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Sexual Dysfunction (SD) 
Outcomes/ Adverse 
Events 
Method used to 
determine SD 
Author, Year 

































Comparison of efficacy and 
tolerability of a fixed dose of 
ESC with SER 
Drugs, Doses, and Range 
D1: ESC (10-20 mg 1 x 
daily): 10 mg QD; Low 
D2: SER (25-200 mg 1 x 
daily): 50-200 mg QD; 












8 week + 1 week lead-in 







 Adults (age range): 18-
80 
 Diagnosed with MDD 
according to DSM-III or 
-IV: DSM-IV 
 MADRS: ¡Ý22 at both 
screening and baseline 






 Negative pregnancy 
test 
 Women of childbearing 
potential not on 







 Use of a depot 
neruoleptic within 6 
months.  
 Use of any neuroleptic, 
antidepressant, or 
anxiolytic medication 
within 2 week (5 weeks 
for FLUOX).  
 Treatment with either 
ESCalopam or SER.  
 Failure to respond to 
adequate trials of any 
two SSRIs.  
 Any psychotropic 
Groups similar at 
baseline 
Yes 
n =  
D1: 107 
D2: 108 
Mean age, years 
D1: 40.6 
D2: 38.1 
Sex, % female 
D1: 54.8% 
D2: 60.2% 




D1: 15.9 (0.5 SE) 
D2: 15.6 (0.5 SE) 
Insomnia, % 
NR 
Concomitant anergia, % 
NR 
Experienced prior 
depressive episodes, % 
NR 
Comments:  





Sexual dysfunction:  
D1: Ejaculation disorder: 




D2: Ejaculation disorder: 
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Sexual Dysfunction (SD) 
Outcomes/ Adverse 
Events 
Method used to 
determine SD 
Dexcept zaleplon or 
zolpidem for sleep. 
 Additional mental 
illnesses or organic 
mental disorder not 
related to depression 
(e.g., schizophrenia, 
bipolar) 
Following were all listed 
as exclusion criteria:  
 Primary Axis I disorder 
other than MDD 
 history of any DSM-IV 
defined psychotic 
disorder 








 Current psychotic 
disorder, personality 
disorder of sufficient 
severity to interfere with 
participation. 
 Illicit drug and alcohol 
abuse: Dependency as 
defined by DSM-IV. 
 Clinically significant 
medical disease 
 Findings from physical 
examination, laboratory 
test, and ECG were 
required to be normal or 
clinically insignificant. 
 Investigational drug use 
within last month. 
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Sexual Dysfunction (SD) 
Outcomes/ Adverse 
Events 
Method used to 
determine SD 
 Suicidal tendencies 
(acute or other) 
Outcome measures 
 HAM-D: HAMD 
baseline; HAMD anxiety 
subscale 
 MADRS 
 CGI-S and CGI-I 
 Quality of life scales: 




 Others: HAM-A; CES-D 
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Method used to 
determine SD 
Analysis and Study 
Quality (Risk of 
Bias) 
Author: 















To compare efficacy, 
safety and tolerability of  
escitalopram at a fixed 
dose of 10 mg/ 
day was compared with 
that of placebo in 
patients with 
MDD in a primary care 
setting 








D2: ESC: 10 mg/d 
Inclusion criteria: 
 Age 18- 65 years 
 Diagnosed with 
MDD according to 
DSM-IV  
 MADRS  total 
scores ≥ 22 and ≤40 
at screening and 
baseline visits 
Exclusion criteria: 












disorder or cognitive 
disorder (according 













hydrate or other 5-
HT receptor 
Groups similar at 
baseline: 
yes 
Mean age (yrs): 
D1: 40 
D2: 41 
Sex (% female): 
D1: 77.8 
D2: 73.8  
Race (% white): 
overal >97% 
Baseline MADRS 22-
29 (moderately ill): 
D1: 59.8 
D2: 57.4  
Baseline MADRS 30-






D2:  3/50 (6% of men) 








at least one dose of 
double-blind study 
medication and 
who had at least one 
post-baseline 
assessment of 
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 MADRS score ≥ 5 
on item 10 (suicidal 
thoughts) 
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Sexual Dysfunction (SD) 
Outcomes/ Adverse 
Events 
Method used to 
determine SD 
Author, Year 

































The objective was to 
examine efficacy and 
tolerability of ESC compared 
to DUL in patients with 
moderate to severe MDD 
patients over 24 weeks, with 
a secondary enpoint at 8 
weeks. 
Drugs, Doses, and Range 
D1: ESC 20 mg/day (Primary 
Analysis- endpoint at 24 
weeks) 
D2: DUL 60 mg/day (Primary 












Type of depression 
MDD 
Intervention 
ESC 20 mg/day 
DUL 60 mg/day 
 
Inclusion criteria: 
 Adults (age range):  
18 - 65 years of age 
 Diagnosed with MDD 
according to DSM-III or 
-IV 
 MADRS: total score 
greater than or equal to 
26 
 CGIS: greater than or 
equal to 4 
 Other: Patients with a 
secondary current 
comorbid anxiety 
disorder could be 
included, except 
obsessive-compulsive 
disorder, post traumatic 










and zaleplon used 
episodically for 
insomnia) within 2 
weeks prior to baseline 
or during study 
 Additional mental 
illnesses or organic 
mental disorder not 
related to depression 
(e.g., schizophrenia, 
Groups similar at 
baseline 
Yes 
n =  
D1: 141 
D2: 146 
Mean age, years 
D1: 43.3 (11.6) 
D2: 44.5 (11.0) 
Sex, % female 
D1: 74.1 
D2: 70.2 




D1: 22.1 (7.6) 
D2: 21.9 (6.5) 
Insomnia, % 
NR 
Concomitant anergia, % 
NR 
Experienced prior 
depressive episodes, % 
NR 
Comments:  
Base on intent-to-treat 
population (ESC, n = 141, 








disorder, libido decrease 
and loss of libido):  
 
D1: 7/144 (4.9%) 
D2: 10/151 (6.6%) 







by the patients or in 
response to a non-leading 
question by the 
investigator 
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Sexual Dysfunction (SD) 
Outcomes/ Adverse 
Events 




disorder or features, 






or cognitive disorder 
 Illicit drug and alcohol 
abuse within 12 months 
prior to baseline 
 ECT within last 6 
months 
 Suicidal tendencies  
 Receiving formal, 
behaviour therapy or 
systematic 
psychotherapy 
 History of lactose 
intolerance, 
hypersensitivity or non-
response to CIT, or 
ESC, or DUL, or with 
increased intra-ocular 





 MADRS: adjusted 
mean change in 
MADRS total score 
from baseline to 24 
weeks 
 CGI-S or CGI-I 
 Quality of life scales: 
MOS 36 - Item Health 
Survey (SF-36) 
Sexual Dysfunction associated with Second-Generation Antidepressants in Patients with Major Depressive Disorder - Results from a Systematic Review with Network Meta-Analysis. 
Drug Safety; U. Reichenpfader, G. Gartlehner, L.C. Morgan, A. Greenblatt, B. Nussbaumer, R. A. Hansen, M. Van Noord, L. Lux, and B. N. Gaynes. Corresponding author: 
 
U. 
Reichenpfader, Department for Evidence-based Medicine and Clinical Epidemiology, Krems, Austria; Department of Medical and Health Sciences - Division of Community Medicine, 












Sexual Dysfunction (SD) 
Outcomes/ Adverse 
Events 
Method used to 
determine SD 












Sexual Dysfunction (SD) 
Outcomes/ Adverse 
Events 
































To compare efficacy and 
tolerability of ESC and CIT in 
outpatients with MDD 
(MDD). 
Drugs, Doses, and Range 
D1: CIT: 10 mg/d 
D2: CIT 20 mg/d 















CIT 10 mg 
CIT 20 mg 
 
Inclusion criteria: 
 Adults (age range): 23 
to 45 
 Diagnosed with MDD 
according to DSM-III or 
-IV: DSM-IV 
 MADRS: Total Score  
25 
 Opinion of treating 
psychiatrist, potential 
benefit from treatment 









 Oral antipsychotic 
drugs or MAOIs w/in 2 
weeks 
 Depot antipsychotic 
preparation within 6 
months 
 SSRI, SNTR, or TCA 
within 1 week or 
FLUOX within 5 weeks 
 Mania or any bipolar 
disorder, schizophrenia, 
Groups similar at 
baseline 
Yes 




Mean age, years 
D1: 35.19  
D2: 34.79 
D3: 35.12 












Concomitant anergia, % 
NR 
Experienced prior 
depressive episodes, % 
D1: 14.8% 
D1: 1/106 (0.9%) 
D2: 1/108 (0.9%) 
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Sexual Dysfunction (SD) 
Outcomes/ Adverse 
Events 


















were not included. 











and one patient 
withdrew due to 







or any psychotic 
disorder, or display of 
any psychotic features,  
 OCD, mental 
retardation or any 
pervasive 
developmental disorder,  
 Eating disorder 
(anorexia nervosa or 
bulimia nervosa), or 
dementia 
 Alcohol or drug abuse 
within previous 12 
months 
 Other serious illnesses 
or sequela of serious 
illness 
 ESC or CIT usage 
within 60 days 
 Severe drug allergies or 
hypersensitivity 
 Inability to comply with 
protocol 
 Undergoing treatment 
with antiparkinsonian 
compound, barbiturate, 
chloral hydrate, lithium, 
anticonvulsant, or 
hypnotic and anxiolytic. 
Outcome measures 
 MADRS: Primary 
efficacy measure. A 
secondary efficacy 
measure was reported 
in changes from 
baseline in total score 
in a subgroup of 
severely depressed 
patients (MADRS total 




MADRS total score, mean 
(SE) 34.78(0.34) 
MADRS total score, mean 
(SE) 35.40(0.32) 
MADRS total score, mean 
(SE)35.70 (0.37) 
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Sexual Dysfunction (SD) 
Outcomes/ Adverse 
Events 
Method used to 
determine SD 
 Also MADRS core 
depressions subscale 
score in overall 
population and severely 
depressed subgroup. 
This data was not 
abstracted but is 
available, if needed. 
 CGI-S or CGI-I: 
Secondary efficacy 
measure. Changes 
from baseline to end of 
study. 
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#1 Search "Antidepressive Agents, Second‐Generation"[MeSH] OR "Fluoxetine"[MeSH] OR 
"Sertraline"[MeSH] OR "Paroxetine"[MeSH] OR "Citalopram"[MeSH] OR "Fluvoxamine"[MeSH] 
OR "Bupropion"[MeSH] OR "nefazodone"[Substance Name] OR "mirtazapine"[Substance 
Name] OR "venlafaxine"[Substance Name] OR "escitalopram"[tw] OR "duloxetine"[Substance 
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